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Abstract 
A key goal in cancer research is to understand the underlying mechanisms of the metastatic 
process, by which cancer cells spread from a primary tumor to other sites and form 
secondary tumors. Indeed, metastasis is responsible for around 90% of cancer patient 
mortality. However, metastatic dissemination is an inefficient process as only a small 
subset of cancer cells leaving the primary tumor has the potential to form metastases. In 
experimental animal models, less than 0.02% of the single tumor cells leaving the primary 
tumor ultimately develop metastases. We have found that cells from primary tumors 
sometimes escape as clusters, and those cell clusters more efficiently form metastases 
compared to single tumor cells. 
Based on our previous findings, we aimed to investigate the ways in which tumors interact 
with the vasculature that would allow the intravasation of polyclonal tumor cell clusters. A 
barrier to answer this question is largely a result of the difficulties in establishing models 
in which the dynamics of tumor-vessel interactions can be visualized and characterized. To 
overcome this barrier, we used of a microfluidic approach with a physiologically and 
morphologically realistic vasculature along with 3D organotypic culture of tumor 
organoids. This device allowed us real-time and quantitative assessment of tumor- vessel 
interactions under in vivo like conditions.  
We observed the dynamics of three types of tumor-vessel interactions: mosaic vessel (i.e., 
partial endothelial cell lining), vessel constriction, and vessel pull. We found that mosaic 
vessels are the most frequent type of tumor-vessel interaction observed in vitro. Moreover, 
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our work shows that tumor cells invade through the vessel wall by integrating and 
displacing the endothelial cell lining suggesting a tumor-endothelial cell junction. 
Furthermore, we were able to observe in real time the passive shedding of a tumor cell 
cluster that preceded mosaic vessel formation. 
This study is the first to show the dynamics of tumor-vessel interactions using a 3D 
microvessel model along with 3D organotypic culture of primary breast cancer tissue. We 
anticipate that deeper understanding of the mechanisms of tumor-vessel interactions along 
with intravasation will provide new insights for targeted anti-metastatic treatments. 
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Understanding the role of the tumor microenvironment in cancer 





Breast cancer is the second leading cause of cancer-related mortality among women 
in the United States. Metastasis is responsible for more than 90% of breast cancer deaths 
(Weigelt et al., 2005; Mehlen and Puisieux, 2006) and the many details governing each 
step of the metastatic cascade remain poorly understood (Wirtz et al., 2011). 
 
Breast cancer is a very heterogeneous disease that varies from each patient. This 
heterogeneity is classified clinically by staging systems and by the histopathologic grade. 
Differential expression of established prognostic and predictive biomarkers, and hormone 
receptors is the basis for targeted treatment. Currently, the focus of treatment relies mostly 
on inducing tumor cell apoptosis. However, there is growing evidence that demonstrates 
the importance of the tumor microenvironment in the development and progression of 
cancer, and consequently, emerging treatments have focused on targeting the tumor stroma 
(Condeelis and Pollard, 2006; Grivennikov, 2016) 
 
To better understand cancer progression, there have been numerous in vivo animal 
and in vitro models developed to study cancer metastasis (Cekanova and Rathore, 2014; 
Denayer et al., 2014). While in vivo animal models better represent the complexity of the 
metastatic process, the visualization and characterization of this multi-step process is 
challenging. The need to improve our understanding of tumor progressions and metastasis 
has pushed for the improvement of in vitro tumor models. These in vitro models vary in 
complexity and incorporate different components of the tumor microenvironment to better 
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approach physiological conditions. (Hulkower and Herber, 2011; Wirtz et al., 2011; 




Metastasis is the main cause of cancer related deaths, accounting for more than 90% 
of cancer mortality (Nguyen, Bos, and Massagué 2009). A complex series of sequential 
steps need to be completed to form a clinically detectable metastatic lesion at a distant 
organ (Valastyan and Weinberg 2011). These steps begin by the invasion of epithelial cells 
in a primary solid tumor into the local stroma, intravasation into the lumen of blood (or 
lymphatic) vessels, surviving during circulation, arrest at a secondary site, extravasation 
into the stroma, and re-initiation of proliferation at the secondary site. 
 
Invasion into the surrounding stroma involves the breaching of the epithelium 
basement membrane (BM), which separates epithelial tissues from the adjacent 
extracellular components. The BM causes alterations in cell polarity, proliferation, 
invasiveness, and survival through a series of signaling pathways activated by cancer cells 
via integrin-mediated cell-matrix adhesion (Wolf and Friedl 2003; Bissell and Hines, 
2011). Recent work indicates that the normal epithelium serves as an intrinsic barrier to 
invasion and dissemination. For example, in the mammary gland, myoepithelial cells are 




Once the BM is breached, tumor cells encounter the stroma. Conventional models 
of cancer metastasis have described the process as the detachment of a single tumor cell 
from the primary tumor that is able to gain access to the circulation and seed a secondary 
site (Poste and Fidler, 1980; Fidler, 2003; Talmadge and Fidler, 2010). This single tumor 
cell model has been challenged by clinical observations of tumor cell clusters (also termed, 
“tumor microemboli”) in the blood of patients, and it has been correlated with poor 
patients’ outcomes (Hou et al., 2012; Aceto et al., 2014). Using a mouse model of highly 
metastatic breast cancer, we (and others) found that metastasis can occur through the 
invasion and dissemination of polyclonal tumor clusters that are able to seed secondary 
sites (Aceto et al., 2014; Cheung et al., 2016). Furthermore, we found that tumor cell 
clusters have > 100-fold metastatic potential compared to single tumor cells. These data 
provide evidence that tumor clusters can escape from primary tumors and seed secondary 
sites as multicellular groups of cells. Despite these intriguing observations, how tumor 
clusters are able to access the systemic circulation is still unknown.  
 
The tumor microenvironment 
 
Since 1889, when Stephen Paget proposed the “seeds” (cancer cells) and “soil” 
(microenvironment) hypothesis, research has been steered to the analysis of the tumor 
microenvironment (TME) that promotes tumor growth and metastasis (Paget, 1889; Hart 
and Fidler, 1980). Tumor cells secrete a plethora of grow factors, such as Transforming 
growth factor beta (TGF-b), Platelet-derived growth factor (PDGF), Vascular Endothelial 
Growth Factor (VEGF) and Epidermal Growth Factor (EGF), among others (Wolf and 
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Friedl, 2003; Hu et al., 2008). The tumor stroma can become “reactive”, acquiring wound 
healing or chronically inflamed traits (Grivennikov et al., 2010).  
 
Tumors invade through this reactive stroma and encounter fibroblasts, adipocytes, 
endothelial cells, bone marrow-derived stem cells, macrophages and other immune cells 
(Joyce and Pollard, 2009). For example, the infiltration of white blood cells has been 
described as an important hallmark of cancer (Balkwill and Mantovani 2001). Studies have 
shown that leukocyte infiltration in breast cancer stimulates tumor invasiveness by the 
secretion of interleukin-6 (IL-6) by adipocytes present in the local microenvironment (Dirat 
et al., 2011). Tumor associated macrophages (TAMs) have been shown to promote 
invasion and dissemination of tumor cells and their presence in breast cancer has been 
associated with poor patient survival (Biswas and Mantovani, 2010). Fibroblasts are 
another predominant stromal cell type found throughout the tumor microenvironment 
which continuously remodel the ECM (Kalluri, 2016). These tumors associated fibroblast 
(CAFs) are considered to be pro-tumorigenic due to the secretion of several cytokines and 
growth factors like Fibroblast Growth Factor (FGF), PDGF, TGF-b, monocyte chemotactic 
protein 1 (MCP1) and many secreted proteases (Olumi et al. 1999; Kalluri and Zeisberg 
2006). 
 
The tumor vasculature 
 
One of the hallmarks of cancer is tumor angiogenesis, which is essential to support 
rapid tumor growth. During early stages of tumor development, access to nutrients and 
 6 
oxygen is supplied by the pre-existing vasculature, termed “vessel co-option”. However, 
once tumors grow beyond 1-2 mm., angiogenesis is triggered by the resulting hypoxic 
conditions, since the diffusion distance of oxygen has been measured to be 100-200 µm 
(Carmeliet and Jain, 2000). Tumors transition from a pre-vascular hyperplastic state to a 
hypervascularization state referred as the “angiogenic switch” (Bergers and Benjamin, 
2003). Tumor cells induce the expression of hypoxia-inducible factor-1 (HIF-1) which 
promotes the expression of pro-angiogenic proteins, such as VEGF, EGF, FGF, hepatocyte 
growth factor (HGF), and PDGF, increasing the signals for neovascularization (Bergers 
and Benjamin, 2003; Itatani, 2018). The sustained expression of pro-angiogenic signals 
results in the development of a vasculature that is abnormal, with a tortuous structure, 
characterized by dilated vessels that show increased vascular permeability and high 
interstitial fluid pressure. This high interstitial fluid pressure further disrupts blood flow 
that eventually increase hypoxic conditions that helps sustain the balance toward pro-
angiogenic factors (Maeda et al., 2000; Snuderl et al., 20013; Dvorak, 2002). 
 
Tumor vasculature has also been shown to exhibit partial endothelial cell lining, a 
structure termed “mosaic vessels” (Chang et al., 2000). For example, analysis of tumor 
vasculature in histological sections of colon carcinoma xenografts showed that 
approximately 15% of the total vessels lacked complete endothelial coverage (Chang et al., 
2000). Other studies, have shown evidence of vessels completely lacking endothelial cell 
lining, termed “vascular mimicry” (Hendrix et al., 2003). These vessels are described to be 
formed by the tumor itself and are characterized by the deposition of BM, vascular 
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endothelial cadherin (VE-CAD), and the formation of connections with existing tumor 
vasculature (Hendrix et al., 2003; Hallani et al., 2010). 
 
Abnormal angiogenesis in solid tumors not only results in structural defects but 
also in functional deficiencies (Folkman, 1995). These vessels are usually leaky, resulting 
in an heterogenous blood flow, and elevated interstitial fluid pressure (Fukumura and Jain, 
2007). Solid tumors often show increased uptake and retentions of nanoparticles or high 
molecular weight probes, known as the enhanced permeability and retention (EPR) effect 
(Hashizume et al., 2000; Wong et al., 2015). Vessel functionality has been studied in 
animal models by measuring the permeability of fluorescent tracer molecules that are 
perfused through the vasculature. 
 
 The tumor vasculature shows low to moderate permeability in the order of 10-6 to 
10-7 cm s−1 for albumin and 70-kDa dextran, respectively (Yuan, 1994).  These studies are 
often limited to peripheral and/or ectopic tumor vasculature, where the vessel endothelium 
is largely intact. Nevertheless, intact tumor vasculature has been shown to have higher 
permeability to normal vasculature and has been shown to be leakier than normal 
vasculature, with defect cut-off sizes of 400–600 nm (Yuan, 1994). This leakiness is 
referred to as the enhanced permeation and retention (EPR) effect and it is widely used in 
the delivery of cancer therapeutics (Wong, 2015). 
 
The 3D tumor microvasculature network has been studied using corrosion casts, 
creating replicas of the tumor vasculature from human colorectal cancers (Folarin et al., 
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2010). This study revealed that the tumor vasculature shows aberrant intervessel spacing, 
tortuosity, and diameter which changes from the periphery to the core of the tumor. 
Histological sections of tumor xenografts from different murine and human tumor cell lines 
have revealed intercellular defects up to 5 μm in size that enable the local extravasation of 
nanoparticles and red blood cells (Folarin et al., 2010). 
 
Vascular structure and function could regulate the mode and frequency of 
intravasation by cancer cells and cancer cell clusters. Intravasation is a process that 
involves the entry of cancer cells into the lumen of lymphatic or blood vessels. 
Intravasation is facilitated by molecular changes that promote the ability of cancer cells to 
cross endothelial cell barriers. Evidence from intravital imaging suggests that intravasation 
is an active process that necessitates the disruption of the endothelium in a process term 
trans-endothelial migration (TEM; Harney, 2015). Other evidence points to intravasation 
as a passive process in which tumor cells and/or clusters are shed into the blood flow due 
to mechanical disruption of fragile vessel walls (Liotta, 1976). 
 
Despite all these intriguing observations, little is known about the dynamics of 
tumor-vessel interactions and how it can influence the pathway for tumor cell entry into 
the cirluation. In vivo assays have been used to analyze the process of intravasation (Ref); 
however, the detailed mechanisms of the cell-cell interactions are difficult to analyze, and 
the dynamics are challenging to capture. The recent development of in vitro models that 
can recapitulate the complexities of the tumor microenvironment provide a platform to 
study these mechanisms that might shed light in the process of intravasation.  
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3D microvessel model to study tumor-vessel interactions 
 
Numerous tumor mouse models have been developed that ranges from genetically 
engineered inducible models to human tumor xenografts (Cekanova and Rathore, 2014; 
Denayer et al., 2014). In vivo models provide the complexity of a living system, but 
visualization and the mechanism of individual steps remain difficult to analyze. In contrast, 
in vitro models can model many aspects of the tumor microenvironment, allowing us to 
study each step of the metastatic cascade while controlling for many variables and 
performing quantitative analysis.  
 
Many in vitro models have been used to provide mechanistic insights in regard to 
tumor growth, invasion, dissemination, matrix remodeling, dormancy, intravasation, 
angiogenesis, and drug delivery. The complexity of the models depends on the objective 
of the study. For drug screening, 2D cell culture provides a low-cost platform; while studies 
of invasion and dissemination are performed with cells embedded in a matrix material 
(Shamir and Ewald, 2014). To analyze solid tumors, the use of 3D models better 
recapitulates cell-cell and cell-matrix interactions (Nguyen-Ngoc, 2015). Studies of tumor-
vessel interactions and intravasation necessitate a microenvironment that incorporates 
perfusable microvessels. The microvessels used to study interactions between tumor cells 
and the tumor vasculature are fabricated by introducing endothelial cells within predefined 
ECM scaffolds within a matrix material (Bogorad et al., 2015). 
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In this study, we generated a cylindrical microvessel, with a diameter of 150-200 
μm, using a template scaffold. These microvessels were developed by seeding endothelial 
cells within a predefined channel, surrounded by a collagen type I gel. Cells seeded on 
these ECM surfaces self-assembled into a continuous monolayer and were tested for 
functional properties, such as vessel permeability, expression of relevant junctional 
proteins (Chrobak et al., 2006). The advantages of these 3D cylindrical microvessels are 
that they exhibit a physiologically relevant geometry, can be maintained under constant 
flow and shear stress, and can be co-cultured with a variety of cell types. In a recent study, 
qualitative observations of invasion and intravasation using this 3D microvessel platform 
found that single tumor cell entry into the vasculature is mediated by tumor cell division at 
the ECM–vessel interface resulting in the disruption of the endothelial monolayer (Wong 
and Searson, 2014).  
 
To study the cellular dynamics of tumor-vessel interactions we used a 3D tumor-
microvessel model that incorporated a functional vasculature within an extracellular matrix 
material as mentioned above. This reductive model combined both a perfusable 
microvessel with freshly isolated mammary gland tumor organoids that were embedded 
into collagen-I gels (Wong and Searson, 2014). In this way, we were able to recapitulate 
both the microvessel cylindrical geometry, endothelium-matrix interactions, shear stress 
and flow, with the 3D structure of tumors (Nguyen-Ngoc et. al, 20015). This approach 
offered us the advantage of being able to monitor tumor-vessel interactions in real time, 
using live cell imaging, partially recapitulating the spatial organization and structure of the 
tumor microenvironment.  
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In this study, we were able to model three types of tumor-vessel interactions: 
mosaic vessel, vessel constriction and vessel pull, each of which may have important 
implications for metastasis. We speculate that tumors that generate sufficient force on the 
endothelium to disrupt endothelial cell-cell junctions could enable the formation of mosaic 
vessel structures which may facilitate shedding of CTCs and/or CTMs exposed to the 
vessel flow without the need of TEM. While vessel constriction may give rise to other 
vascular defects such as dead-ends, vessel pull could be a mechanism used by highly 
adherent tumor cells to co-opt pre-existing vessels. Additionally, the state of the 
endothelium may contribute to the formation of any of these tumor-vessel structures. For 
example, if the endothelium had a net increase in cell death rate, it could facilitate the 
integration of tumors within the vasculature. On the other hand, if the rate of proliferation 
was higher and the overall state of the vessel was intact, tumors could interact with the 
endothelium by constricting or pulling on the vessel wall. Our experimental approach 
enables a convenient way to study multiple steps in the metastatic cascade that are 
otherwise very difficult to observe in vivo. Moreover, this tumor-microvessel model could 
also be adapted and customized to reflect other aspects of the tumor microenvironment to 
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Mosaic loss of non-muscle myosin IIA and IIB is sufficient to  
induce mammary epithelial proliferation  
 
(Modified from Nguyen-Ngoc, K.V.*, V.L. Silvestri*, D. Georgess, A.N. Fairchild, 
and A.J. Ewald. 2017. Mosaic loss of non-muscle myosin IIA and IIB is sufficient to 




The mammary epithelium elaborates through hormonally-regulated changes in 
proliferation, migration, and differentiation. Non-muscle myosin II (NMII) functions at the 
interface between contractility, adhesion, and signal transduction. It was therefore a 
plausible regulator of mammary morphogenesis. We tested the genetic requirement for 
NMIIA and NMIIB through deletion of the myosin heavy chains (NMHC) that confer 
specificity to the complex. Surprisingly, mosaic loss, but not ubiquitous loss, of NMHCIIA 
and IIB induced high levels of proliferation in 3D culture. This phenotype was observed 
even in basal media conditions that do not support tissue level growth of wildtype 
epithelium. Mosaic loss of NMIIA and IIB combined with FGF signaling to induce 
hyperplasia. Mosaic analysis revealed that both NMIIA,B-null and wild-type cells 
proliferated, indicating that the regulation of proliferation is both cell autonomous and non-
autonomous within epithelial tissues. This phenotype appears mediated by cell-cell contact, 
as co-culture did not induce proliferation. Mosaic loss of NMIIA and IIB also induced 
excess proliferation in vivo. Our data therefore reveal a role for NMIIA and NMIIB as 








Cell proliferation and tissue architecture need to be tightly regulated to ensure 
normal development and homeostasis. Excessive proliferation is a hallmark of cancer and 
can be induced by constitutive activation of mitogenic signals, inactivation of growth 
suppressors, or escape from contact inhibition of proliferation (Hanahan and Weinberg, 
2011). For example, loss of the cadherin/catenin complex can induce uncontrolled 
proliferation and tumor growth (Jeanes et al., 2008). However, most genetic studies of 
proliferation have been conducted in conventional 2D cell culture, which only partially 
recapitulate the structure and dynamics of epithelial tissues. The molecular mechanism by 
which cells sense and regulate proliferation in three-dimensional (3D) tissues remains 
incompletely understood.  
Non-muscle myosin II (NMII) is expressed in most cell types and plays an essential 
role in diverse cellular processes including contractility, adhesion, cytokinesis, migration, 
and signal transduction (Lecuit and Yap, 2015; Ma and Adelstein, 2014). NMII exists in 
three isoforms: NMIIA, NMIIB, and NMIIC. Each NMII isoform is composed of three 
pairs of proteins: two regulatory light chains, two essential light chains, and two heavy 
chains (Vicente-Manzanares et al., 2009). The specificity of the NMII complex is 
determined by the identity of the heavy chain, which in mammals can be encoded by three 
genes: NMII heavy chains A, B, and C (NMHC IIA, IIB, IIC). NMII molecules bind to and 
crosslink the actin cytoskeleton to form networks of actomyosin filaments, which support 
cell architecture and function (Vicente-Manzanares et al., 2009). In single cell migration, 
NMII molecules orchestrate integrin-mediated adhesion to extracellular matrix (ECM) 
substrates (Choi et al., 2008) to ensure directional movement (Yam et al., 2007). In 
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multicellular systems, such as epithelia, NMIIs are required for the establishment and 
maintenance of apical junctions in early developing tissues, such as the visceral endoderm 
(Conti et al., 2004) and the spinal neuroepithelium (Ma et al., 2007) and in mature organs 
such as the epidermis (Sumigray et al., 2012).  
Using a variety of genetic tools, including isoform specific ablation and 
replacement, Adelstein and colleagues have discovered both specific and redundant 
functions of NMII isoforms (Ma and Adelstein, 2014). For example, NMIIA and NMIIB 
are interchangeable in regulating spinal neuroepithelial intercellular junctions (Ma et al., 
2007) whereas NMIIA is uniquely required for mouse placental blood vessel formation, 
and NMIIB is uniquely required for neuronal cell migration (Ma et al., 2004). Exchanging 
the two isoforms only partially rescues organ defects in the non-redundant cases. Distinct 
molecular functions of NMIIA and NMIIB have also been found during the spatio-
temporal regulation of E-cadherin-based junction in epithelial sheets (Smutny et al., 2010). 
These findings demonstrate the importance of NMII molecules in epithelial tissue 
architecture and function, and also stimulate questions about how loss of NMII could 
disrupt tissue homeostasis and promote pathogenesis.   
Disruption of NMII-mediated cellular contractility is associated with diverse 
diseases, including cancer. Cell adhesion to the ECM activates myosin and Rho/ROCK 
signaling, enabling NMII to mediate both extracellular adhesion and mechanical signals 
and thereby affect cell behavior (Vicente-Manzanares et al., 2009). Recent studies have 
also discovered multiple roles for NMII in cancer. For example, sustained elevation of 
NMII-mediated cellular tension in response to increasing matrix stiffness and rigidity can 
promote cell proliferation and tumorigenesis (DuFort et al., 2011). NMIIA and NMIIB 
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have distinct roles in force generation and nuclear translocation during cancer invasion 
(Thomas et al., 2015). Finally, inducible expression of p190-B Rho GTPase disrupted 
mammary tissue architecture resulting in increased cell proliferation (Vargo-Gogola et al., 
2006). In contrast, reduced contractility due to loss of NMIIA in a tumor susceptible 
background promotes cell proliferation and metastasis in squamous cell carcinoma 
(Schramek et al., 2014). This emerging evidence indicates that NMIIA can be a tumor 
suppressor; however, the genetic consequences of NMII loss in the normal mammary 
epithelium remain unclear.  
Here we sought to understand the role of NMII in epithelial organization and 
development, using the mammary epithelium as a model system. We combined 3D culture 
of primary epithelial organoids with adenoviral delivery of Cre-recombinase (Ad-Cre) and 
time-lapse imaging to reveal the cellular consequence of NMII deletion in mammary 
epithelium. Surprisingly, we found that mosaic deletion of NMIIA and NMIIB is sufficient 




Isoform specific deletion of NMII in mammary organoids 
The mammary epithelium consists of two major cell types: an inner luminal 
epithelial cell layer, surrounded by a basally-positioned myoepithelial cell layer. We first 
examined the expression and localization of NMII isoforms A, B, and C within these 
epithelial populations using both NMIIA-GFP and NMIIB-GFP knock-in mice and 
immunofluorescent staining to detect endogenous proteins. Consistent with previous 
reports (Beach et al., 2011), NMIIA was expressed in both luminal and myoepithelial cells, 
NMIIB was predominantly observed in myoepithelial cells and at low levels near the apical 
limit of the luminal cell membranes, and NMIIC was restricted to the luminal epithelial 
cell layer (Supplemental Figure 2-1 A-C).  
 
To study the consequences of loss of NMII in the mammary epithelium, we used 
Ad-Cre to delete the NMHCIIA and NMHCIIB genes in primary mammary organoids, 
which are fragments of primary epithelial ducts embedded within 3D ECM gels (Matrigel; 
Figure 2-1 1A). In these assays, organoids will not grow in basal medium without 
supplemental growth factor addition (No GF) and will undergo branching morphogenesis 
in response to FGF2 (Ewald et al., 2008; Nguyen-Ngoc et al., 2015). Since the heavy chain 
confers the specificity of the NMII complex, we refer to the deletion of NMHCIIA and 
NMHCIIB and loss of NMIIA and NMIIB interchangeably.  
 
We isolated mammary epithelial organoids from mice carrying floxed NMHCIIA 
and NMHCIIB alleles, and a ubiquitously expressed tamoxifen-inducible Cre recombinase 
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(Cre-ER;NMIIAfl/fl;NMIIBfl/fl). Organoids from the same mouse were initially evaluated in 
three groups: control (Untreated), Ad-Cre and tamoxifen (Tam) treatments in basal 
medium. Infections with Ad-Cre were designed to yield Cre expression in 50-75% of cells 
(Badea et al., 2003; Shamir et al., 2014). We refer to the organoids treated with Ad-Cre as 
mosaic NMIIA,B-null organoids. Tamoxifen induced Cre-ER activity resulted in 
recombination in essentially all cells. Western blotting confirmed the loss of NMIIA and 
NMIIB proteins in Tam treated organoids, and a reduction in both proteins in the Ad-Cre 
treatment group, while NMIIC protein levels remained unchanged in both treatments 
(Figure 2-1 B-C). To analyze the effects of loss of NMIIA and IIB in mammary epithelial 
organoid growth, we measured the fold increase in projected surface area of organoids at 
day 5 divided by day 0 in culture. We observed a significant increase in growth of mosaic 
organoids compared to control and Tam treatment, respectively (Figure2-1 1D and 
Supplemental Figure 2-2 A,C,D). In contrast, control and Tam did not show significant 
increase in tissue size. To control for the effects of adenoviral infection, we separately 
evaluated the consequences of Ad-GFP infection and found no effect on tissue growth 
(Supplemental Figure 2-2 B,G). To control for the effects of Tam on tissue growth, we 
isolated mammary epithelial organoids from wild-type mice not carrying loxP-flanked 
NMHCIIA and NMHCIIB alleles and treated with 50nM Tam. At the dose used, Tam did 
not have an effect on organoid growth (Figure 2-1 1D and Fig. Supplemental Figure 2-2 





Mosaic loss of both NMIIA and NMIIB is sufficient to induce hyperproliferation in 
the mammary epithelium  
We investigated the consequences of loss of NMIIA and/or NMIIB in basal 
medium conditions (Nguyen-Ngoc et al., 2015). Control epithelial organoids typically 
maintained their size (Figure 2-1 E). Deletion of two or three alleles of the NMHCIIA and 
NMHCIIB genes did not grossly affect organoid size (Figure 2-1 F-J). In contrast, mosaic 
deletion of all four alleles of NMHCIIA and NMHCIIB genes resulted in tissue growth 
(Figure 2-1 K and Figure 2-2 A). Strikingly, complete deletion of NMIIA and NMIIB in 
the Tam treated organoids did not affect organoid growth, while mosaic deletion with Ad-
Cre resulted in large increase in organoid projected surface area by day 5 in culture (Figure 
2-1 D and Supplemental Figure 2-2 C,G). Consistent with this level of tissue growth, 
mosaic NMIIA,B-null organoids had a higher mitotic index than control organoids, as 
assayed by phospho-Histone H3 staining (pH3, Figure 2-2 B-D). Taken together, these data 
indicate that loss of NMIIA and NMIIB in a mosaic subset of cells is sufficient to induce 
extensive proliferation in the mammary epithelium, even in basal medium conditions.  
 
Mosaic loss of NMIIA and NMIIB combined with exogenous FGF2 induces 
hyperplasia 
During puberty, mammary epithelial cells undergo branching morphogenesis in 
response to proliferative signals mediated through steroid hormones and growth factors 
(Sternlicht et al., 2006). We have previously shown that this process can be modeled 
through addition of nanomolar concentrations of FGF2 in our “branching” assay (Ewald et 
al., 2008; Nguyen-Ngoc et al., 2015). Addition of FGF2 in control organoids induced cell 
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division and resulted in the formation of branched epithelial structures (Supplemental 
Figure 2-2 H), with a corresponding increase in projected surface area relative to initial 
size (~4 fold, Figure 2-2 E). Deletion of 1-3 alleles of NMHCIIA and NMHCIIB genes 
correlated with a non-significant reduction in tissue growth and was compatible with 
relatively normal branching (Supplemental Figure 2-2 I-M). In contrast, mosaic deletion 
of all four alleles in FGF2 treated organoids led to a significant increase in tissue growth 
(~9 fold), inferred from the change in projected surface area of organoids in time-lapse 
movies (Figure 2-2 E and Supplemental Figure 2-2 N). Consistent with the tissue growth 
in time-lapse movies, mosaic NMIIA,B-null organoids had a higher mitotic index than 
control organoids, as assayed by pH3 staining (Figure 2-2 F-H). These data demonstrate 
that loss of both NMIIA and NMIIB, combined with growth factor signaling, further 
promote excess proliferation. Taken together, we conclude that NMIIA and NMIIB 
cooperatively serve as negative regulators of proliferation within the mammary epithelium. 
 
Mosaic loss of NMIIA and NMIIB induce both cell autonomous and non-autonomous 
proliferation within the mammary epithelium 
We next asked whether the excess proliferation was limited to NMIIA,B-null cells. 
To address this question, we introduced a convertible double-fluorescent Cre reporter into 
the floxed myosin II line, NMIIAfl/fl;NMIIBfl/fl;mTmG. In this model, all cells constitutively 
express membrane-localized tdTomato (red fluorescence) and, upon Ad-Cre treatment, 
switch heritably to expression of membrane-localized green fluorescent protein (GFP). 
Therefore, green fluorescence serves as a direct reporter for Cre activity and an indirect 
reporter for NMHCIIA and NMHCIIB genes deletion. NMIIAfl/fl;NMIIBfl/fl;mTmG 
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organoids were treated with Ad-Cre to generate a mixture of red and green cells. Mosaic 
organoids were then embedded in 3D Matrigel in basal medium. This strategy allowed us 
to identify which population of cells, wild-type (red, Cre-) or NMIIA,B-null (green, Cre+), 
contributed to the overgrowth phenotype (Figure 2-3 A). 
 
Since we observed a significant increase in proliferation in Ad-Cre treated 
organoids by 70-80 hours in culture (Figure 2-2 A), we collected fluorescent confocal z-
stack images at day 3 and day 5 (Figure 2-3 B,D). To calculate the contributions of wild-
type and NMIIA,B-null cells, we measured the total volume of each population of cells for 
each mosaic organoid at day 3 (initial volume) and day 5 (final volume) of culture using 
3D surface rendering (Figure 2-3 C,E). Using initial and final surface-rendered volumes of 
wild-type and NMIIA,B-null cells (Figure 2-3 F,G), we calculated and compared growth 
rates. We found that the % change in volume for NMIIA,B-null cells was 101.5% 
compared to 41% for wild-type cells (Figure 2-3 H). Time-lapse movies also confirmed 
that the increase in volume was due to increased cell proliferation and not cell growth 
(Supplemental Figure 2-3 A-C). We validated successful completion of cytokinesis by 
evaluating cell shapes in 3D in confocal time-lapse movies and speculate that it could be 
accomplished due to residual NMIIC (Figure 2-1 B). We conclude that loss of NMIIA and 





Hyperproliferation induced by mosaic loss of NMIIA and NMIIB is not mediated by 
soluble factors 
Having demonstrated that wildtype and NMIIAB-null cells proliferate in response 
to mosaic loss of NMIIA and IIB within an organoid, we next sought to determine whether 
this effect was mediated by soluble factors. To test this hypothesis, we used the 
NMIIAfl/fl;NMIIBfl/fl;mTmG line to generate both wild-type (containing only red cells) and 
Ad-Cre treated organoids (mixture of red and green cells) for mosaic NMIIA,B deletion as 
previously described. We then co-cultured wild-type and mosaic organoids in a 1:1 ratio 
in 3D Matrigel with basal medium (Figure 2-4 A). Confocal microscopy images were taken 
at day 5 in culture (Figure 2-4 B-D). To analyze differences in growth, we measured the 
projected area of organoids in co-culture compared to wild-type (control) and mosaic 
(control) organoids, respectively. We observed a consistent and significant 2.5-fold 
increase in growth of mosaic organoids in both monoculture and co-culture, relative to 
wild-type (Figure 2-4 E). In contrast, wild-type organoids essentially did not increase in 
size in either monoculture or co-culture (Figure 2-4 E). Taken together, these data suggest 
that the hyperproliferation caused by mosaic deletion of NMIIA and NMIIB in mammary 
organoids is not mediated by soluble factors but is instead likely mediated by cell-cell 







NMIIA,B deletion increases sporadic cell proliferation in epithelial ducts in vivo 
Our genetic analysis in 3D culture revealed that mosaic loss of NMIIA,B resulted 
in excess proliferation in both wild-type and NMIIA,B-null cells. We next tested the 
consequences of NMIIA,B deletion in polarized mammary epithelium in vivo. We isolated 
and orthotopically transplanted organoids from Cre-ER;NMIIAfl/fl;NMIIBfl/fl;mTmG and 
CreER;NMIIAfl/+;mTmG (control) mice into the cleared mammary fat pad of 
nonfluorescent host mice. We allowed six weeks for ductal network formation, then 
induced NMIIA,B deletion by tamoxifen injection and, waited an additional six weeks 
before collecting mammary glands (Supplemental Figure 2-4 A) to assay proliferation by 
pH3 staining. Similar to the organoids cultured in basal medium without additional growth 
factors, control epithelium contained very few pH3+ mitotic cells (Supplemental Figure 2-
4 B-C). In contrast, epithelium where NMIIA and NMIIB were deleted displayed an 
increased number of mitotic cells (Supplemental Figure 2-4 B’-C’). We calculated the 
number of proliferative cells per 40x field of view and observed a statistically significant 
increase following loss of NMIIA and NMIIB (Supplemental Figure 2-4 D). Finally, 
proliferation was observed in both red (Cre-) and green (Cre+) cells demonstrating that the 
effect of NMIIA,B deletion on proliferation was also both cell autonomous and non-
autonomous in vivo (Supplemental Figure 2-4 E’-G). The magnitude of the increase in 
proliferation and the associated disruption of epithelial architecture were both smaller in 
vivo compared to in vitro. We speculate that this difference is due to the presence of 
additional negative regulators of proliferation, to differences in the extent of mosaicism in 




Our genetic analysis of NMII was motivated by previous pharmacologic studies in 
which inhibition of myosin activity disrupted branching morphogenesis in multiple organs 
(Daley et al., 2009; Ewald et al., 2008; Meyer et al., 2006; Michael et al., 2005; Moore et 
al., 2005). Our data support the concept that NMII can function as a negative regulator of 
proliferation. NMII mediated tension regulates the establishment and dynamics of 
intercellular junctions (Smutny et al., 2010) and loss of junctional components such as E-
Cadherin (Derksen et al., 2006) accelerates mammary tumor progression. Cell tension 
derived from NMII-based contractility is required to support these adhesion complexes and 
also responds to the forces generated by adjacent cells and the ECM (Lecuit and Yap, 
2015). Therefore, either an elevation or reduction of myosin activity could change cell 
behavior and tissue organization. We therefore speculate that mosaic but not ubiquitous 
loss of NMII isoforms could induce proliferation by destabilizing intercellular junctions or 
disrupting mechanotransduction. 
NMIIA and NMIIB are essential for multiple functions at the cell and tissue level, 
and so deletion of all four alleles may be statistically unlikely in cancer cells. However, a 
similar heterogeneity in myosin activity across the tissue could be achieved through clonal 
loss of myosin inhibitors or clonal gain of activators. These mechanisms would phenocopy 
the effect of NMIIA,B deletion in a subset of cells and could drive clonal fixation in either 
the myosin-deficient or neighboring myosin-normal cells. As an example, overexpression 
of p190-RhoB induced hyperplasia in the mammary epithelium (Vargo-Gogola et al., 
2006). Given the ubiquity of disruptions in Rho GTPase signaling in human cancer (Sahai 
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and Marshall, 2002; Vega and Ridley, 2008), we speculate that heterogeneity in myosin 
levels between neighboring cells could be a major driver of cancer cell proliferation. 
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Materials and methods 
 
Mouse strains 
The NMIIAfl/fl, NMIIBfl/fl, NMIIA-GFP and NMII-GFP knock-in mouse lines (Jacobelli et 
al., 2010; Ma et al., 2009) were a gift from R. Adelstein (National Heart, Lung, and Blood 
Institute, NIH, Bethesda, MD). The R26::Cre-ER mouse line was a gift of J. Nathans 
(Johns Hopkins University; Baltimore, MD). The FVB/NJ, mT/mG (Muzumdar et al., 
2007) and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse lines were acquired from the 
Jackson Laboratory. Mouse husbandry and procedures were all conducted according to an 
animal protocol approved by the Johns Hopkins University School of Medicine 
Institutional Animal Care and Use Committee. 
3D culture assays of primary mammary epithelial organoids 
We used a combined mechanical and enzymatic digestion using collagenase (C2139; 
Sigma-Aldrich) and trypsin (27250-018; Gibco Life Technologies), followed by 
differential centrifugation to isolate groups of mammary epithelial ducts, termed organoids, 
as previously described (Ewald et al., 2008; Nguyen-Ngoc et al., 2015). Organoids were 
then embedded in 3D MatrigelTM (354230; Corning) at 2-3 organoids/µL as 150 µL 
suspensions in a 24-well multiwell glass bottom plate (662892; Greiner Bio-One) or 2-well 
chamber coverglass (155379; ThermoFisher Scientific). Gels were allowed to polymerize 
for 30 minutes at 37°C and then cultured in minimal medium: DMEM/F12 (10565-018, 
Gibco), 1% v/v insulin, transferrin, selenium (51500, ThermoFisher) and 1% v/v 
penicillin/streptomycin (15140-122, Gibco). Basal medium conditions (No GF) refer to 
organoids embedded in growth factor-reduced Matrigel and cultured in minimal medium 
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without the addition of supplemental growth factors. For branching morphogenesis assay, 
minimal medium is supplemented with 2.5 nM FGF2 (F0291, Sigma). 
Tamoxifen-inducible Cre-mediated deletion in 3D culture 
Cre activity was induced in Cre-ER;NMIIAfl/fl;NMIIBfl/fl;mT/mG mammary epithelium by 
culturing organoids embedded in 3D Matrigel with 50 nM tamoxifen (T5648; Sigma-
Aldrich) for 18 hours. Cultures were then rinsed with PBS to wash out tamoxifen and 
incubated in fresh organoid medium for 5 days at 37°C. The tamoxifen-inducible system 
resulted in Cre activity in essentially all cells but did not have obvious morphological 
consequences for wildtype organoids. 
Adenoviral gene delivery 
As previously described (Huebner et al., 2016; Shamir et al., 2014), prior to embedding in 
3D Matrigel, organoids were infected with Adenoviral-GFP or Adenoviral-CMV-Cre 
(Vector BioLabs) at the ratio of ~107 PFU per 1000 organoids. Infections were conducted 
in 50 µL DMEM for 1.5 hours at 37°C. Following viral treatment, organoids were washed 
twice in DMEM-F12 and suspended in Matrigel as previously described. 
Orthotopic transplantation to mammary fat pad 
For transplantation of mammary organoids followed by induction of gene deletion, we 
isolated and incubated organoids overnight at 37°C in organoid medium with 2.5 nM FGF2 
in HydroCell 96-well microplates (174907, Thermo Fisher Scientific). The next day, 
organoids were suspended in a 50% DMEM: 50% Matrigel solution at a density of 20-30 
organoids/µL and kept on ice throughout the procedure. We conducted orthotopic 
transplantations into 3- to 4-week-old NSG mice in a sterile hood. In brief, mice were 
anesthetized with 2- 2.5% isoflurane and immobilized, the surgical site was cleaned with 
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ethanol. The mammary gland was exposed by a 1-cm mid-sagittal cut followed by a 0.5-
cm oblique cut from the initial incision to one hip. The skin was then retracted to expose 
the number 4 mammary gland. The number 5 gland and the lymph node in the number 4 
gland were removed. 10-20 µL of organoid suspension was injected into the number 4 
gland using a syringe (702RN[7636–01]; Hamilton; custom 1-in needles, 26 gauge). The 
skin was then locally infiltrated with 5–10 μL of 0.25% bupivacaine. The same procedure 
was repeated in the contralateral mammary gland. For each mouse, we transplanted control 
organoids (Cre-ER;NMIIAfl/+;mTmG) in one gland and experimental organoids (Cre-
ER;NMIIAfl/fl;NMIIBfl/fl;mTmG) in the other. The wounds were closed with 9-mm 
autoclips. Triple antibiotic ointment was applied to wounding sites. Deletion of NMIIA 
and NMIIB in mature ductal networks was accomplished six weeks post transplantation by 
injection of 100 µL of 10mg/mL tamoxifen i.p every other day for 5 days (three total 
injections) using a 1 mL syringe and a 30G1/2 needle (305106; BD). Glands were harvested 
6 weeks after tamoxifen injection.  
Differential interference contrast (DIC) microscopy 
Time-lapse imaging was performed with an LD Plan-Neofluar 20×/0.4 Korr Ph2 objective 
lens and a Cell Observer system with an AxioObserver Z1 and an AxioCam MRM camera 
(Carl Zeiss). In general, 100-200 positions were captured in parallel at 20-min intervals  for 
5 days. Temperature was set at 37°C and CO2 at 5%. AxioVision (Carl Zeiss) was used to 
acquire and analyze the movies, place scale bars, and export time frames as TIFFs. 
Photoshop CS6 (Adobe) was used to adjust levels and brightness across entire images to 
maximize image clarity.  
Confocal microscopy 
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Confocal imaging was conducted on a spinning-disk confocal microscope (Solamere 
Technology Group Inc.) with an XR/MEGA-10 S30 camera (Stanford Photonics, Inc.), as 
previously described (Ewald, 2013). A Fluar 20×/0.75 objective lens (Carl Zeiss) was used 
for intermediate magnification images, an LD C-Apochromat 40×/1.1 W Korr objective 
lens (Carl Zeiss) for high magnification single and time-lapse image acquisition, with water 
and ImmersolTM W 2010 (Zeiss) used as the imaging mediums, respectively. Acquisition 
was done with a combination of µManager (Edelstein et al., 2010) and Piper (Stanford 
Photonics, Inc.). For time-lapse imaging to observe cell division, images were captured at 
20 minutes intervals for 16-18 hours, and temperature was set at 37°C and CO2 at 5%. 
Imaris (Bitplane) was used to analyze images, add scale bars, and export individual TIFFs. 
Photoshop CS6 (Adobe) was used to adjust levels and gamma for each channel, across the 
entire image, to maximize image clarity. 
Immunofluorescence staining 
Organoids and mammary gland tissues were collected, fixed, and stained as previously 
described (Nguyen-Ngoc et al., 2015). Briefly, organoids embedded in 3D Matrigel and 
whole mammary glands were fixed in 4% paraformaldehyde for 15 minutes and 3 hours, 
respectively. The samples were then rinsed three time with PBS for 10 min, embedded in 
Optimal Cutting Temperature compound (OCT), and stored at -80°C. OCT blocks were 
sectioned at 100 µm thickness for cultured organoid samples and 50 µm thickness for gland 
tissue. Sections were placed on Superfrost Plus Gold microscope slides (15-188-48; 
Fisherbrand) and stored at -80°C. For antibody staining, slides were thawed at ambient 
temperature, rinsed twice with PBS to remove OCT and permeabilized with 0.5% Triton 
X-100 for 1 hour. Samples were then blocked with 10% FBS/1% BSA in PBS for 2-3 hours 
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and incubated with primary antibody solution overnight at 4°C in 1% FBS/1%BSA in PBS. 
Slides were then rinsed twice in PBS with 10% FBS/1% BSA and then incubated with 
secondary antibodies diluted in PBS with 1% FBS/1% BSA overnight at 4°C. Slides were 
rinsed twice in PBS with 1% FBS/1% BSA for 10 minutes and once in PBS for 10 minutes, 
mounted with Fluoromount (F4680; Sigma-Aldrich), and sealed with coverslips. Nuclei 
were stained with DAPI (1:1000, D3571, Invitrogen). Immunofluorescent staining for each 
antibody was done for at least three independent biological replicates. Mouse anti-
Phospho-Histone H3 (1:300, 9706L, Cell Signaling Technology) was used as primary 
antibody and Alexa Fluor-647 goat anti-mouse (1:200, Invitrogen) as secondary antibody.   
Protein extraction 
Lysis buffer was prepared by diluting 10x RIPA buffer (20-188; EMD Millipore) with 
ultrapure water and incubation on ice for 2 hours. Immediately before addition to cell 
pellets, lysis buffer was supplemented with 0.1% SDS, 5% glycerol, 3 mM EDTA, 1 mM 
NaF, 1 mM PMSF, 1.5 mM NaVO4, Aprotinin (A6279; Sigma-Aldrich), and a mini 
protease inhibitor tablet (11836153001; Roche). Organoids embedded in 3D Matrigel were 
collected for protein extraction as follows: the medium was aspirated, the gels were rinsed 
once with 1 mL cold PBS, and then dissolved in 1 mL cold PBS/EDTA buffer (5 mM, 1 
mM NaVO4, 1.5 mM NaF, and 1 mM PMSF in PBS). The suspensions were then 
transferred to centrifuge tubes, mixed well by pipetting, incubated on a shaker for 1 hour 
at 4°C, and centrifuged at 1500 rpm for 5 minutes at 4°C. Supernatants were removed and 
pellets were suspended with 50-100 µL of RIPA lysis buffer. The suspension was left on 
ice for 40-60 minutes and vortexed every 10 minutes. Tubes were centrifuged for 10 
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minutes at 13,000 rpm at 4°C. Supernatants were transfered to another tubes and stored at 
-80°C.  
Western bloting  
Cel lysates  were thawed  or  directly  used after  preparation.  Samples  were  mixed  with 
Laemmli sample bufer (161-0747; Bio-Rad Laboratories), β-mercaptoethanol and heated 
at  70°C for  10  minutes.  Samples  were loaded for equal amount  of  protein  based  on 
bicinchoninic acid (BCA) analysis (Thermo  Fisher  Scientific) in in  4–15%  Mini-
PROTEAN TGX precast gels (456-1084; Bio-Rad Laboratories). SDS-PAGE was run at 
115V for  1  hour.  Gels  were transfered  onto Immobilon-FL  membranes (IPFL07810; 
Milipore) at  100  V for  1  hour at  4°C.  Membranes  were  blocked in  10  mL  Odyssey 
Blocking Bufer for 1 hour at room temperature on shaker before incubated with primary 
antibody in 50:50 Odyssey Blocking Bufer/TBST at 4°C overnight. Primary antibodies 
used were rabbit anti-NMIA (1:1000; 909801; BioLegend), rabbit anti-NMIB (1:1000; 
909901; BioLegend), rabbit anti-NMIC (1:1000; 919201; BioLegend) and mouse anti- 
Tubulin (1:1000; T5201; Sigma). Membranes were washed three times with TBST for 5 
min, before incubated with secondary antibodies (IR-conjugated Licor) in 50:50 Odyssey 
blocking  bufer/TBST for  1  hour at room temperature  on shaker.  Secondary antibodies 
used  were  goat anti-Rabbit  800CW (1:10,000,  827-08365;  Licor) and  goat anti-Mouse 
680RD (1:10,000; 926-68170; Licor). Membranes were then washed twice with TBST for 
5 minutes and once with TBS for 5 minutes, before being imaged wet on the Licor Odyssey 
CLx. Bands were quantified using ImageJ.  
Quantification and statistical analysis 
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Image analyses were performed using imageJ and Imaris software (Bitplane Scientific, 
Zurich, Switzerland). All statistical analyses were conducted using STATA or Graphpad 
Prism. Data was evaluated for normality using D'Agostino-Pearson omnibus test. P value 
was determined by one-way ANOVA or Mann-Whitney test if the data did not presented 
a normal distribution. P <0.05 was considered significant. Column plots report s.e.m. All 
data represent at least three biological replicates. 
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Figure 2-1. Concurrent loss of both NMIIA and NMIIB in a subset of cells in the 
mammary epithelium is sufficient to induce tissue growth.  
(A) Schematic representation of 3D organotypic culture of Cre-ER;NMIIAfl/fl;NMIIBfl/fl 
mammary epithelial organoids in basal medium (No GF). Organoids from the same mouse 
are divided into three groups for control (Untreated), adenoviral Cre recombinase (Ad-Cre) 
or tamoxifen (Tam) treatments. Ad-Cre was used to accomplish mosaic recombination and 
tamoxifen induced the Cre-ER to recombine ubiquitously. (B) Representative western blot 
and (C) protein quantification showing a reduction of NMIIA and NMIIB proteins levels 
in organoids after Ad-Cre and Tam treatments, respectively. (n= 3 mice. Whole organoid 
lysate samples were loaded for equal protein based on BCA analysis). (D) Mammary 
organoid growth was evaluated by fold increase in projected surface area of organoids at 
day 5 divided by day 0 in culture. Data are presented as mean+/-s.d. ns, non-significant. n, 
number of organoids summed across three biologically independent experiments 
(P<0.0001, one-way ANOVA). (E-K) Still images from time-lapse movies of organoids 
carrying different combinations of NMIIA and NMIIB floxed alleles, treated with Ade-Cre 
in basal medium without growth factor. Scale bars: (E-K) 50µm. 
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Figure 2-2. Mosaic loss of NMIIA and IIB induces proliferation in mammary 
organoids cultured in basal medium or with FGF2 supplementation.  
(A) The growth rate of organoids carrying different numbers of floxed alleles of NMIIA 
and NMIIB treated with Ad-Cre in basal medium (No GF) was determined by measuring 
organoid projected surface area normalized to initial size. (B-C) Confocal images of 
mammary organoids in basal medium stained to label proliferation (pH3, green) and nuclei 
(blue). (D) Fold increase in pH3+ cells of organoids in basal medium was calculated by 
dividing the number of pH3+ cells per number of cells per organoid compared to control. 
(E) The growth rate of organoids carrying different numbers of floxed alleles of NMIIA 
and NMIIB treated with Ad-Cre in FGF2 supplemented medium was determined by 
measuring organoid projected area normalized to the initial size. (F-G) Confocal images of 
organoids in FGF2 supplemented medium stained to label proliferation (pH3, green) and 
nuclei (blue). (H) Fold increase in pH3+ cells of organoids in FGF2 supplemented medium 
was calculated by dividing the number of pH3+ cells by the organoid projected surface 
area compared to control. n, number of organoids summed across three biologically 
independent experiments. Stars highlight the significant difference in growth rate across 
samples within the same time point. White dash lines mark the shape of organoids. Error 
bars indicate s.e.m. [P<0.0001, one-way ANOVA (A), (E)]. [P<0.0001, Mann-Whitney 




Figure 2-3. Heterogeneous loss of NMIIA and NMIIB induces proliferation of both 
NMIIA,B-null and wildtype cells within the mammary epithelium.  
(A) Organoids isolated from Cre-ER;NMIIAfl/fl;NMIIBfl/fl;mTmG mice were treated with 
Ad-Cre to generate a mixture of Cre- (red) and Cre+ (green) cells. Mosaic organoids were 
plated in 3D Matrigel in basal medium (No GF) to test cell autonomy. There were 3 
potential outcomes: i) Cre+ dominant, ii) Cre- dominant or iii) a mixture of both Cre+ and 
Cre- cells. (B and D) Representative 3D Projection and (C and E) 3D surface rendering of 
mosaic organoid at day 3 and day 5 in culture. (F-G)  Plots of initial and final surface-
rendered volumes of red and green cell, respectively. (H) Percent change in volume of Cre- 
and Cre+ cells. Error bars indicate s.e.m. P value determined by the Mann–Whitney test. 












Supplemental Figure 2-1. Expression and localization of NMII isoforms in the 
mammary epithelium.  
Mammary epithelial ducts were imaged to show localization of (A’) NMHIIA-GFP 
(located in both luminal and myoepithelial cells), (B’) NMHIIB-GFP (located in 
myoepithelial and in luminal cells at the apical membrane), and (C’) stained for NMHIIC 
(located predominantly in luminal epithelial cells). (A’’-C’’) F-actin and (A’’’-C’’’). 



























Supplemental Figure 2-2. Mosaic deletion of both alleles of NMIIA and NMIIB 
induces proliferation in organoids cultured in basal medium or with FGF2 
supplementation.  
(A-D) Representative still images of mammary organoids from Cre-
ER;NMIIAfl/fl;NMIIBfl/fl mice for control (Untreated), adenoviral GFP (Ad-GFP, adenoviral 
control), adenoviral Cre recombinase (Ad-Cre) and Tamoxifen (Tam) treatments. (E-F) 
Representative still images of mammary epithelial organoids from wild-type mice not 
carrying loxP-flanked NMHCIIA and NMHCIIB alleles for control (Untreated) and Tam 
treatment. (G) Mammary organoid growth in basal medium was evaluated by fold increase 
in projected surface area of organoids at day 5 divided day 0 in culture. Images and data 
correspond to figure 1D. Data are presented as mean+/-s.d., ns, non-significant. n, total 
number of organoids for 3 mice (P<0.0001, one-way ANOVA). The data for Cre-
ER;NMIIAfl/fl;NMIIBfl/fl organoids in the Untreated, Ad-Cre, and Tam conditions are 
duplicated from Figure 1D for ease of comparison. (H-N) Representative still images from 
time-lapse movies of organoids carrying different genetic variants of NMHIIA and NMHIIB 




Supplemental Figure 2-2. 
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Supplemental Figure 2-3. NMIIA and NMIIB double deletion induces proliferation 
of both wild-type and NMIIA,B null cells in mosaic organoids.  
(A) Frames from a representative confocal time-lapse movie of a mosaic NMIIA,B-null 
organoid in basal medium conditions. (B) Insets of the red channel to depict cell division 
in wild-type cells. (C ) Insets of the green channel to depict cell division in NMIIA,B-null 






Supplemental Figure 2-4. NMIIA,B deletion increases spontaneous proliferation in 
vivo.  
(A) Schematic description of orthotopic transplantation and inducible gene deletion. (B-C) 
Representative images of different epithelial structures found in the control glands. (B’-C’) 
Representative images of epithelial structures with pH3+ cells found in NMIIA,B deleted 
glands. (D) The average number of pH3+ cells per epithelial duct imaged at 40x 
magnification. (E-F) Different section views of the same epithelial duct. (E’-F’) Insets of 
proliferating (pH3) NMIIA,B-null (Cre+) and wild-type (Cre-) cells. (G) Fold increase in 
proliferating Cre- and Cre+ cells within NMIIA,B-null epithelium. Error bars indicate 
s.e.m. P<0.0001, Mann–Whitney test. n, number of fields summed across three biologically 
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Polyclonal breast cancer metastases arise from collective dissemination 
of keratin 14 expressing tumor cell clusters 
 
(Modified from Cheung, K.J., V. Padmanaban, V. Silvestri, K. Schipper, J.D. 
Cohen, A.N. Fairchild, M.A. Gorin, J.E. Verdone, K.J. Pienta, J.S. Bader, and A.J. 
Ewald. 2016. Polyclonal breast cancer metastases arise from collective dissemination 
of keratin 14-expressing tumor cell clusters. Proceedings of the National Academy of 




Recent genomic studies challenge the conventional model that each metastasis must arise 
from a single tumor cell and instead reveal that metastases can be composed of multiple 
genetically distinct clones. These intriguing observations raise the question: How do 
polyclonal metastases emerge from the primary tumor? In this study, we used multicolor 
lineage tracing to demonstrate that polyclonal seeding by cell clusters is a frequent 
mechanism in a common mouse model of breast cancer, accounting for >90% of 
metastases. We directly observed multicolored tumor cell clusters across major stages of 
metastasis, including collective invasion, local dissemination, intravascular emboli, 
circulating tumor cell clusters, and micrometastases. Experimentally aggregating tumor 
cells into clusters induced a >15-fold increase in colony formation ex vivo and a >100-fold 
increase in metastasis formation in vivo. Intriguingly, locally disseminated clusters, 
circulating tumor cell clusters, and lung micrometastases frequently expressed the 
epithelial cytoskeletal protein, keratin 14 (K14). RNA-seq analysis revealed that K14+ 
cells were enriched for desmosome and hemidesmosome adhesion complex genes, and 
were depleted for MHC class II genes. Depletion of K14 expression abrogated distant 
metastases and disrupted expression of multiple metastasis effectors, including Tenascin C 
(Tnc), Jagged1 (Jag1), and Epiregulin (Ereg). Taken together, our findings reveal K14 as 
a key regulator of metastasis and establish the concept that K14+ epithelial tumor cell 




During metastasis, cancer cells escape the primary tumor, travel through the 
circulation, and colonize distant organs. Conventional models of cancer progression 
propose that each metastasis arises from the clonal outgrowth of a single tumor cell and 
this conceptual framework is a foundation for models, such as epithelial-mesenchymal 
transition (EMT) and migratory cancer stem cells (1). Challenging the generality of the 
single-cell/single-metastasis model are long-standing clinical observations that tumor cell 
clusters (also termed “tumor clumps”) are also observed across the stages of metastasis. 
Tumor cell clusters are detected in the bloodstream of cancer patients (2), clusters can 
efficiently seed metastases (3), and though rare, circulating tumor cell (CTC) clusters have 
prognostic significance (4, 5). Furthermore, metastases are composed of multiple 
genetically distinct tumor cell clones, in mouse models of breast, pancreas, and small cell 
carcinoma (5–7), and in human metastatic prostate cancer patients (8). Taken together, 
these observations provide accumulating evidence that tumor cell clusters contribute to 
metastasis. However, they leave unresolved two important questions: how do tumor cell 
clusters emerge from the primary tumor, and which molecular features identify cell clusters 
that metastasize? 
 
An important clinical observation is that cancer cells invade the surrounding stroma 
as cohesive clusters in the majority of epithelial tumors, a process termed “collective 
invasion” (9, 10). In breast cancer, collective invasion is facilitated by invasive leader cells, 
a subpopulation of tumor cells that highly express keratin 14 (K14) and other basal 
 58 
epithelial markers (11). K14+ cells are migratory, protrusive, and lead trailing K14− cells, 
while maintaining cell–cell cohesion and E-cadherin–based cell contacts. 
 
In this study, we sought to understand how these K14+ cells exit collective invasion 
strands in the primary tumor and travel to distant organs (12). One hypothesis is that 
collective invasion is an intermediate step toward eventual single-cell dissemination and 
monoclonal metastasis. However, tumor cell clusters are detected in circulation (5) and 
primary human breast tumors can disseminate collectively into the surrounding 
extracellular matrix in ex vivo assays (13–15). These data prompted an alternative 
hypothesis, that collectively invading K14+ cancer cells could initiate and complete the 
metastatic process as a cohesive multicellular unit. Here we define the clonal nature of 
metastases in a spontaneous mouse model of metastasis to the lungs (16, 17), in which the 
predominant invasive form in the primary tumor is collective invasion strands led by K14+ 
cells (11). We establish that the majority of metastases arise from polyclonal seeds, and 
show that disseminated tumor cell clusters are predominantly composed of K14+ cells. We 
propose a mechanism for polyclonal metastasis via the collective invasion, dissemination, 




Multicolor fluorescent lineage tracing identifies frequent polyclonal metastasis in a 
mouse model of breast cancer 
To define the clonal origin of metastasis in a model of collective invasion, we developed a 
multicolor lineage-tracing strategy in a commonly used mouse model of breast cancer, 
MMTV-PyMT, which has provided fundamental insights into diverse aspects of metastatic 
progression (16, 17). In this model, the MMTV promoter drives mammary epithelial 
expression of the polyoma virus middle T antigen (PyMT), a potent activator of PI3K 
signaling, a hallmark of human breast cancer. The mammary tumors formed in this model 
show gene expression most similar to luminal B, an aggressive subtype of human breast 
cancer prone to metastasis (18). 
 
We generated a convertible double-fluorescent mammary tumor model, 
ROSAmT/mG;MMTV-PyMT, in which tumor cells express membrane-localized tdTomato 
(mTomato) and, upon treatment with adenoviral Cre recombinase (adeno-Cre), switch 
heritably to expression of membrane-localized enhanced GFP. ROSAmT/mG;MMTV-PyMT 
tumor organoids were treated with adeno-Cre to generate a mixture of red and green cells. 
Mosaic organoids were then injected orthotopically into the cleared mammary fat pad of 
nonfluorescent host mice. Because the host is nonfluorescent, this experimental system 
enabled us to unambiguously identify tumor metastases and their clonal origin (Fig. 1A). 
The principle of this strategy is that if there is an obligate single-cell intermediate during 
the metastatic process, we would expect to see a transition from a multicolored primary 
tumor (red and green) to singly red or green metastases. 
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In the lungs of these mice, we detected single disseminated tumor cells, 
micrometastases (2–50 cells), and macrometastases (>50 cells). Single disseminated tumor 
cells were 47-fold more frequent than metastases (range 10- to 150-fold, n = 10 mice). We 
reasoned that if lung metastases arose exclusively from seeding of single disseminated 
tumor cells, then each lung metastasis should express only one color. In contrast, 
multicellular seeding should be able to produce metastases with both colors. Interestingly, 
we observed lung metastases composed of both red and green tumor cells across a range 
of sizes, from 2 cells to >1,000 cells per metastasis (Fig. 1B) (n = 375 multicolored 
metastases). Multicolored metastases demonstrated significant intermixing of red and 
green tumor cells. Transplanted mice showed wide variation in the percentage of 
multicolored metastases from a minimum of 0% to a maximum of 61% (n = 158 
multicolored out of 257 metastases). Taken together, our data show that multicolored 
metastases can occur frequently in the MMTV-PyMT model. 
 
To understand our variable frequency of detection of multicolored metastases, we 
analyzed the degree of mixing of red and green tumor cell clones at each step in our 
experiments. Whereas red and green tumor cells were well mixed in the recombined tumor 
organoids used as input (Fig. 1C), the tumors that resulted from transplanting these 
organoids showed surprisingly wide variation in the mixing of red and green tumor cells. 
We observed tumors composed almost entirely of a single color to tumors with significant 
intermixing of red and green zones (Fig. 1D). To analyze this variation further, we 
quantified the local mixing of red and green cells within each tumor. Local mixing was 
assessed in 100 × 100-pixel (1.3 mm × 1.3 mm) regions tiled across the tumor by 
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calculating the probability of selecting two colors when pixel values were chosen at random 
within each region. We observed a strong linear correlation between the extent of local 
mixing and the percentage of detected multicolored metastases (Fig. 1E). Thus, local 
proximity between clones of different colors in the primary tumor determines our ability 
to detect multicolored metastases. Based on our analysis of the relationship between local 
mixing and the detection of multicolored metastases (Fig. 1E), we estimate that >97% of 
metastases were formed from multicellular seeds (95% confidence interval 74–100%). 
 
We also determined the frequency of multicolored metastases in two additional 
transplant models. In MMTV-PyMT tumors expressing the Confetti lineage reporter (Fig. 
S1A), tumor cells are induced by adeno-Cre to one of five distinct possible colors: 
cytoplasmic red fluorescent protein (RFP), cytoplasmic yellow fluorescent protein (YFP), 
nuclear GFP (nGFP), membrane cyan fluorescent protein (mCFP), or an unrecombined no-
color (19). We observed zonal patches of a single color in the primary tumor, with a clear 
preference for the unrecombined no-color (Fig. S1B). Even with this limitation, we 
observed lung metastases composed of both no-color and RFP+ tumor cells (Fig. S1C). In 
MMTVPyMT tumors expressing the Rainbow reporter (Fig. S1D), adeno-Cre induces 
recombination to one of 21 different color values (20). Despite the increased color 
diversity, we similarly observed zonal patches of a single color in the primary tumor, with 
preference for a no-color tumor cell (Fig. S1E). In the lungs of these mice, we observed 
multiple metastases composed of one to four different colors (Fig. S1F). Taken together, 
data from three distinct lineage analyses reveal polyclonal metastases in this genetically 
engineered mouse model of breast cancer metastasis.  
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Polyclonal lung metastases arise from multicellular seeds and not by serial seeding of 
single tumor cells 
The multicolored metastases that we observed could arise via the serial seeding of 
single tumor cells or via colonization by a multicellular cluster of tumor cells. We sought 
to distinguish these mechanisms in two different ways. To model stochastic serial seeding 
events integrated over time, we first isolated organoids from different MMTV-PyMT 
tumors that constitutively expressed either mTomato or CFP. We then transplanted 
mTomato+ tumor organoids to the right flank and CFP+ tumor organoids to the left flank 
of a nonfluorescent host (Fig. S2 A and B). Interestingly, we observed a small degree of 
colonization of CFP+ primary tumors by mTomato+ cancer cells, accounting for 1–5% of 
the total tumor area, determined macroscopically in 5 of 11 mice (Fig. S2B, Lower, and 
Fig. S2 C and C′). These data are consistent with the reported ability of metastases to reseed 
primary tumors, termed “tumor self-seeding” (21). Importantly, when we examined the 
clonal composition in the lungs, we only observed single-colored metastases (Fig. S2D). 
Taken together, these data establish that polyclonal metastases do not efficiently arise from 
serial seeding. 
 
To extend this finding, we modeled serial seeding by waves of disseminated tumor 
cells in the bloodstream. In this second experimental approach, we transplanted mTomato+ 
and CFP+ tumor cells serially via tail-vein injection (Fig. S2E). mTomato+ tumor cells 
were isolated by FACS and then injected as a singlecell suspension into a nonfluorescent 
host. Two days later, CFP+ tumor cells were isolated by FACS and injected as a single-
cell suspension into the same mice. Three weeks later, lungs were collected and analyzed. 
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In the lung, we observed exclusively single-colored metastases (Fig. S2E). Therefore, serial 
delivery of cancer cells to the lungs was not an efficient mechanism for generation of 
polyclonal metastases. In agreement with a recent study revealing metastases from 
oligoclonal clusters in breast cancer cell lines (5), our data are most consistent with a model 
in which polyclonal metastases occur via colonization by multicellular seeds rather than 
serial arrival and aggregation of single tumor cells. 
 
Direct observation of polyclonal collective invasion, polyclonal disseminated tumor 
emboli, and polyclonal CTC clusters 
Having shown that polyclonal metastases arise from multicellular seeding, we next 
asked how multicellular seeds emerge from the primary tumor. To answer this question, 
we identified tumor cell clusters across stages of metastasis, starting from collective 
invasion at the primary tumor stromal interface. Consistent with our local mixing analysis 
(Fig. 1 D and E), when we imaged at single-cell resolution, transplanted tumors were 
composed of zonal patches and collective invasion strands were typically composed of a 
single color. Despite this technical barrier to detection of polyclonal groups, we observed 
multicolored collective invasion at interfaces between regions of red and green cancer cells 
(Fig. 2A). In these regions, we reasoned that there were two outcomes at the tumor–stromal 
interface corresponding to two distinct models for the collective invasive-disseminative 
transition (Fig. 2B). One possibility is that tumor cells invade collectively but that 
dissemination occurs obligately through single cells. In this case, because disseminated 
clusters should arise only from focal proliferation of single cells, disseminated clusters 
should be exclusively composed of singly red or green tumor cells. Alternatively, cancer 
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cells could both invade and disseminate collectively as multicellular units. In this case, we 
would expect to identify multicolored disseminated clusters. 
 
To distinguish these possibilities, we analyzed disseminated tumor cell clusters at 
three different stages of the metastatic sequence. First, we observed multicolored 
disseminated tumor cell clusters ≤200-μm away from the tumor–stromal interface, which 
we confirmed were fully disconnected from the primary tumor by 3D reconstruction (Fig. 
2C). Next, we examined the adjacent vasculature at the tumor–stromal interface (Fig. S3 
A–C). We observed both multicolored tumor microemboli and tumor macroemboli 
composed of >100 tumor cells within vessels (Fig. 2D and Fig. S3D). Consistent with their 
collective organization, we observed membrane-localized E-cadherin in collectively 
invading cancer cells, locally disseminated clusters, and tumor emboli (Fig. 2E). As a proof 
of concept, we next isolated CTCs from the systemic circulation of a mouse bearing 
fluorescently labeled tumors. Although this tumor had quite limited local mixing of blue 
and red clones, we identified both a multicolored and multiple singly colored CTC clusters 
(Fig. 2F). We analyzed CTC cluster size in three mice and found that they ranged from 2 
to 66 cells per cluster, with a median of 6 cells (Fig. 2G). Taking these data together, our 
lineage-tracing studies enabled us to observe multicolored tumor cell clusters at five 
different stages of metastasis: collective invasion, locally disseminated clusters in the 
adjacent stroma, intravasated tumor emboli, CTC clusters, and distant micro- and 
macrometastases.  
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Aggregating tumor cells into clusters promotes colony formation ex vivo and lung 
metastatic colonization in vivo 
An important question raised by these experiments is: why are multicellular seeds 
advantageous for metastatic colonization? This question is interesting because tumor cells 
typically maintain extensive cell-cell contacts in vivo, and the organization of epithelial 
cells into cohesive clusters promotes tissue growth in a variety of normal and tumor 
contexts. For example, doublets of Paneth and Lgr5+ stem cells enhance the organoid-
forming potential of single Lgr5+ stem cells (19) while the survival of colonic tumor 
organoids is dependent on retaining E-cadherin contacts (22). 
 
To model the colonization efficiency of multicellular seeding, we developed an 
experimental system to aggregate single tumor cells into cell clusters. Briefly, we isolated 
FACs-sorted single mTomato+ MMTV-PyMT tumor cells and incubated them overnight 
in a nonadherent dish to form cell clusters (Fig. 3A). Overnight incubation increased the 
median number of cell clusters by >15 fold relative to the input single cells (Fig. S4A and 
B). The tumor cell clusters that resulted had a median size of 2 cells, and ranged from 2-
60 cells in size (Fig. S4B’). Importantly, co-incubation of red and green tumor cells 
confirmed that clusters were generated by aggregation rather than by clonal expansion of 
single tumor cells (Fig. S4C). Further, the experimentally determined percentages of 
multicolored clusters as a function of cluster size matched the predicted percentages, 
assuming random assortment of red and green tumor cells into clusters (Fig. S4C’). 
Incubation in a non-adherent dish therefore induces the efficient aggregation of single 
cancer cells into clusters. We next used this approach to compare the efficiency of colony 
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formation by single cells or aggregated clusters, while holding the total cell number 
constant in each condition at 10,000 cells per well. Because each cluster is formed from 
multiple cells, the total number of starting seeds is lower in the aggregated condition when 
compared with the single cell condition. Despite this disadvantage, when cultured in 3D 
Matrigel, we observed that clusters were >15 fold more efficient at forming colonies when 
compared with single tumor cells (Fig. 3A and B). Thus, in an ex vivo setting cluster 
organization strongly enhances colony formation. 
 
To assess metastatic efficiency in vivo, we next injected into the tail veins of 
nonfluorescent host mice either a single cell suspension of mTomato+ tumor cells or an 
equal number of mTomato+ tumor cells that had been aggregated into clusters in vitro. We 
assessed lung metastatic burden at 3 weeks (Fig. 3C). Single cell suspensions generated 0-
1 metastases per mouse (Fig. 3D-E). In contrast, aggregated clusters generated many large 
macroscopic mTomato+ metastases with >100 fold increase in metastatic efficiency 
relative to single cells (Fig. 3D-E). Taken together, these data indicate that cluster 
organization is sufficient to significantly enhance tumor cell survival and promote 
metastasis formation. 
 
Locally disseminated tumor cell clusters, CTC clusters, and micrometastases are 
enriched for K14+ cells, relative to macrometastases 
Given the frequency of polyclonal metastases and the efficiency of metastasis 
formation by multicellular seeding, we next sought to determine the molecular 
characteristics of the multicellular seed. In MMTV-PyMT tumors, K14+ cells account for 
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approximately 2% of the total tumor cell population (11). These K14+ tumor cells lead 
>88% of collective invasion strands extending into the surrounding stroma (11). Consistent 
with the pioneer function of K14+ cells during metastasis, we observed K14+ cells in 
polyclonal collective invasion, disseminated tumor cell clusters, and intravascular emboli 
(Fig. S5A). We also observed significant differences in K14 expression between single 
cells and disseminated clusters, with 2% and 59% expressing K14 respectively (Fig. S5B). 
In addition, we observed that 94% of CTC clusters contained K14+ cells (N=15 of 16 CTC 
clusters, Fig. 2H). The fraction of cells within the cluster that were K14+ decreased as the 
size of the cluster increased (Fig. 2H). Our data therefore show that K14+ cells are enriched 
in the dissemination stages of metastasis. 
 
In lung metastases, the proportion of K14+ cells relative to the total cell number 
varied systematically with the size of the metastasis (Fig. 4A-B). In the primary tumor, 
micrometastases, and macrometastases, K14+ cells accounted for 0.9%, >50%, and 2.5% 
of cells respectively (Fig. 4C). Thus, K14+ cells are highly enriched in locally disseminated 
clusters, CTC clusters, and micrometastases relative to their frequency in the primary 
tumor, and the proportion of K14+ cells reverts to baseline in macrometastases. 
 
To model these transitions in 3D culture, we next isolated single K14- and K14+ 
cells by FACS from MMTV-PyMT tumors that genetically encode for a fluorescent 
biosensor for K14 expression (Figure 4D and S5C) (11, 23). Accordingly, we observed that 
for individually purified K14- and K14+ populations, colony formation was >16-fold 
higher in aggregated clusters relative to single tumor cells (Fig. 4E). In contrast, colony 
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formation was not significantly different for K14- single cells versus K14+ single cells, or 
for K14- aggregated cells versus K14+ aggregated clusters (Fig. 4E). Together, our data 
reveal that the difference in colony formation between K14- and K14+ cells is small 
relative to the difference between multicellular clusters and single cells. 
 
One interpretation of these data could be that the interaction of K14- and K14+ 
tumor cells may synergistically enhance the efficiency of colony formation. Motivating 
this hypothesis, Wnt-driven murine mammary tumors contain two subclones that show 
interclonal cooperation during tumor progression (24). To test the synergy hypothesis, we 
employed our aggregation assay to test the effect of aggregating equal mixtures of K14- 
and K14+ cells (Fig. 4D). However, mixing K14- and K14+ cells in aggregating clusters 
did not significantly enhance colony formation relative to either pure K14- or K14+ cell 
clusters (Fig. 4E). 
 
Alternatively, phenotypic transitions between differentiation states could blunt our 
ability to detect differences in colony formation (25). We therefore examined K14 
expression in aggregated tumor cells at day 0, day 1 post aggregation (Fig. S5D), and at 
day 8 (Fig. S5E). Interestingly, cell clusters at day 1 already contained mixtures of K14- 
and K14+ cells regardless of whether isolated K14- cells, K14+ cells, or mixtures of both 
cell types were used as input (Fig. S5D). Similarly, at day 8, >80% of colonies were 
composed of mixtures of K14- and K14+ cells in each condition (Fig. S5E). 
Morphologically, small colonies were primarily composed of K14+ cells and larger 
colonies were composed of an inner core of K14- cells and an outer layer of K14+ cells 
 69 
(Fig. 4F). Concordant with our observations of metastases in vivo, the proportion of K14+ 
cells varied with the size of clusters grown in 3D Matrigel. In small clusters 2-5 cells in 
size, 100% of cells were K14+ and in larger clusters with ≥ 20 cells, all clusters contained 
multiple K14- cells (Fig. 4G). Thus, isolated K14- and K14+ cells converge toward cell 
colonies composed of both cell states, with K14+ cells predominant in small colonies in 
culture and in micrometastases. Conversely, K14- cells are predominant in large colonies 
and in macrometastases. 
 
The transcriptional program of K14+ tumor cells is enriched for desmosome and 
hemidesmosome adhesion complex genes, and depleted for genes involved in MHC 
class II immunosurveillance 
Given the enrichment for K14+ cells in disseminated tumor cell clusters and 
micrometastases, we next asked how the transcriptional profiles of K14+ and K14- cells 
differed. To answer this question, we compared the transcriptomes of K14+ and K14- cells 
from primary MMTV-PyMT tumors. To focus our attention on changes in gene expression 
between cancer cell subpopulations, we first isolated epithelial organoids from the tumor 
and then used differential centrifugation to deplete immune and fibroblastic stromal cells. 
We then processed these organoids to single cells and FACS-sorted them based on K14 
status. As expected, quantitative RT-PCR revealed that the K14+ cell fraction exhibited 
>12-fold higher levels of K14 RNA expression (Fig. 5A). Our RNA-seq analysis revealed 
239 genes differentially expressed between K14- and K14+ cells at a genome wide 
significance level of P < 10-6 (mean-variance normalized heatmap in Fig. 5B). By DAVID 
gene ontology (GO) analysis (26), we identified significantly enriched GO categories in 
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each cell subpopulation (Table S1). This analysis revealed significant enrichment for genes 
involved in extracellular matrix proteins, intermediate filament organization, and epithelial 
differentiation in K14+ cells. Interestingly, K14+ cells were enriched for transcripts 
encoding TNC, POSTN, and CTGF, proteins required in the metastatic niche (27–29). In 
addition, DAVID analysis revealed a number of genes involved in the regulation of the 
immune system that were significantly depleted in K14+ cells (Table S1). These GO 
categories included immune response, MHC class II antigen presentation, T-cell activation, 
and genes involved in chemotaxis. Genes involved in MHC class II presentation were 
among the most depleted in K14+ cells (Fig. 5C′′). Our data reveal that K14+ cells differ 
across multiple molecular programs that could be advantageous across distinct steps in 
metastasis, including immune evasion. Furthermore, two key features distinguishing K14+ 
cells from the bulk tumor cells are their increased expression of both cell–cell and cell–
matrix adhesion genes. 
 
We also tested the extent to which the K14+ cell transcriptome correlated with 
“stemness” in three ways (30, 31). First, we looked at the expression of putative stem cell 
markers in K14− and K14+ cells. We observed that CD44 was differentially expressed 
between these cell populations, but CD49f, CD24a, CD133, and CD29 were not (Fig. S6A). 
Next, we tested for gene set enrichment in K14− and K14+ cells with published mouse 
mammary stem cell gene sets (Fig. S6B). Our gene set tests revealed that K14− cells were 
enriched for fetal mammary stem cell and luminal epithelial gene signatures. In contrast, 
K14+ cells were enriched for mammary stem cell, adult mammary stem cell, and 
myoepithelial gene signatures. A third approach we took to test stemness was to assay the 
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ability of isolated single K14− and K14+ cells to form mammospheres, as in Spike et al. 
(31) (Fig. S6C). Our data show that both K14− and K14+ cells form mammospheres and 
that the mammosphere-forming efficiency was not significantly different between K14− 
and K14+ cells (Fig. S6D). Taken together, our findings are consistent with a model in 
which stemness features are observed in both K14− and K14+ cells, and that both cell types 
are capable of colony formation. 
 
K14 expression is required for distant metastasis and regulates gene expression of 
multiple metastasis effectors 
Our gene expression study revealed that K14+ cells displayed coordinated 
upregulation of most desmosome (10/11) and hemidesmosome (10/12) complex genes 
(Fig. 5C and C') (32). These observations were intriguing to us because (i) K14 is the major 
intermediate filament in hemidesmosomes, (ii) leader cells require expression of basal 
epithelial genes including K14 for their collective invasive behavior (11), and (iii) a recent 
study has implicated desmosomal function in CTC clusters from human cancer patients 
(5). 
To test the hypothesis that K14 expression is required for distant metastasis, we 
transplanted mTomato+ tumor organoids, either expressing control Luciferase or K14 
shRNA, into host mice (Fig. 6A). Primary tumors derived from Luciferase control 
knockdown organoids did not show statistically significant differences in size compared to 
primary tumors derived from K14 knockdown tumor organoids (Fig. 6B). In contrast, K14 
knockdown tumors had a 7-fold reduction in the mean number of metastases relative to 
control knockdown tumors (Fig. 6C). 
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Having shown that K14 expression is required for distant metastasis, we next asked 
whether knockdown of K14 altered gene transcription. We determined the transcriptomes 
of luciferase control knockdown and K14 knockdown tumor organoids by RNA-Seq and 
identified 1584 genes differentially expressed between conditions (mean-variance 
normalized heatmap in Fig. 6D). To dissect this list further, we next ranked genes by their 
association with Krt14 transcript levels (487 genes at an FDR < 0.05). The top four genes 
most correlated with Krt14 transcript expression were enriched for multiple major 
metastasis effector genes that promote metastatic niche remodeling (Tnc, AdamTs1, Jag1) 
and metastasis survival (AdamTs1, Birc5) (Fig. 6D’) (27, 29, 33, 34). Thus, disruption of 
K14 expression abrogates the expression of multiple metastasis effectors. 
 
To identify the core molecular program expressed in K14+ cells and regulated by 
K14 expression, we then integrated this transcriptome data with our RNA-seq enrichment 
data for K14+ cells. We identified 14 genes with 2 fold or greater significant enrichment 
in K14+ cells and whose gene expression was significantly associated with Krt14 transcript 
levels (Figure 6E). Consistent with our observations in the K14 knockdown dataset, we 
observed that 9 of these genes were previously reported in metastasis regulation, including 
in metastatic niche, vascular remodeling, and immunosurveillance, including Tnc, 
AdamTs1, Jag1 as well as Card10, Cav1, Ereg, Lgr5, Slpi, and Ptgs2 (29, 35-38). Core 
genes showed evidence of multiple physical and genetic interactions and occurrence along 
common pathways (Fig. S7A). Interestingly, the gene most highly enriched in K14+ cells 
and positively regulated by Krt14 transcript levels was Dsg3, which encodes for the major 
desmoglein in desmosomes. Thus, K14 expression also regulates the expression of a major 
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desmosome component. Taken together our data establish that K14 expression is required 
for distant metastasis and that K14 is a regulator of multiple genes that function at distinct 




A major goal of our study was to determine how breast cancer cells seed distant 
metastases. Our lineage analysis enabled us to identify polyclonal collective invasion 
strands, polyclonal disseminated tumor cell clusters in the stroma, polyclonal CTC clusters, 
and polyclonal micro- and macrometastases. Our findings, in conjunction with recent 
reports in CTC clusters (5), and genomic sequencing of metastases (7, 8), provide strong 
evidence for polyclonal seeding as a major mechanism for metastatic spread. 
 
We next focused on the molecular features of the tumor cell clusters that give rise 
to polyclonal metastases. We have previously established that the cells leading collective 
invasion near uniformly express K14 (11). We reveal profound and systematic changes in 
the relative proportions of K14+ and K14− cells from micrometastatic to macrometastatic 
stages. We detect K14+ cells in disseminated tumor cell clusters, in intravascular tumor 
emboli, CTC clusters, and in micro- and macrometastases. Importantly, both CTC clusters 
and micrometastases are >20-fold enriched for K14+ cells relative to primary tumors or 
macrometastases. Thus, K14+ cells are significantly enriched in breast cancer cells during 
the phases of metastasis most associated with systemic spread. Conversely, K14− cells are 
significantly enriched in the phases of metastasis most associated with proliferation. Our 
in vivo data cannot distinguish between conversion of cells from a K14+ to a K14− state 
after arrival in the lung versus expansion of K14− cancer cells that arrived as a component 
of a mixed K14+/K14− cluster. However, our ex vivo assays provide clear evidence for 
interconversion between epithelial states in both directions. The molecular mechanisms 
that drive transitions between K14+ and K14− states are an important area for further study. 
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In our study, we also revealed transcriptomic differences between K14− and K14+ 
tumor cells and identified genes coding for protein complexes distinct to each 
compartment. Concordant with a recent report on plakoglobin, our data implicate the 
desmosome in polyclonal seeding (5). Intriguingly, K14+ cells are also enriched for 
hemidesmosome complex genes and genes encoding for proteinaceous extracellular 
matrix, and K14 expression is required for gene expression of multiple metastasiseffectors 
involved in niche remodeling (29, 37). It is likely that polyclonal tumor cell clusters 
provide an efficient nidus for interactions with collagen I, fibroblasts, macrophages, 
endothelial cells, and other tumor microenvironmental components in the multicellular 
seeding process (39-44). 
 
Our data do not exclude the possibility of single-cell seeding events by either EMT 
or migratory stem cells. However, our lineage analysis does put an upper limit on the 
relative contribution of these events to metastasis in the MMTV-PyMT model. In 
agreement with our data, a recent study used lineage analysis in spontaneous mouse models 
of breast cancer to reveal that EMT does not significantly contribute to the formation of 
lung metastases in MMTV-PyMT mice, and that inhibition of EMT through miR-200 
overexpression does not impair the ability of MMTV-PyMT tumor cells to form metastases 
(45). However, it remains technically prohibitive to image the transit of a cancer cell 
continuously from escape out of the primary tumor through to establishment of a distant 
site, and so some inference remains necessary to construct models of the process. 
Accordingly, it is important to acknowledge contrary observations. We observe K14− 
single cells in the mammary stroma and real-time intravital imaging was recently used to 
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observe single MMTV-PyMT cancer cells intravasating at sites of macrophage–endothelial 
cell connections (44). Our data are compatible with a model in which K14 is required for 
collective invasion and dissemination, but not single cell dissemination. Furthermore, our 
data do not exclude the possibility of transitions between single cell and multicellular 
organization in the mammary stroma before intravasation. Future studies are needed to map 
the relative frequency of different single-cell and multicellular configurations and their 
molecular features across the entire mammary fat pad and in different cancer models 
 
The simplest interpretation of our data is that breast cancer metastases form via the 
local dissemination, entry into circulation, and distal seeding of a multicellular cluster 
containing K14+ cancer cells (Figure S8). Within this framework, the survival advantage 
of multicellular organization provides a mechanism by which genetically distinct clones 
can jointly found a micrometastasis. Eradicating polyclonal micrometastases in the 
adjuvant setting will be particularly challenging when these founders have intrinsic 
differences in treatment sensitivity. Our findings also have potential clinical implications 
for patients with metastatic disease. CTC clusters have prognostic value in multiple tumor 
types (46). Finally, it will be important in future studies to determine how tumor cell 
clusters gain access to the lymphatic and venous circulation. 
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Materials and Methods 
Mouse Lines and Breeding 
Mice used in this study were backcrossed onto and maintained on the FVB/NCrl 
background in a specific pathogen-free facility. Animal protocols were approved by the 
Johns Hopkins University IACUC. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) 
(23), B6(D2)-Tg(CAGBrainbow1.0) 2Eggn/J (Rainbow) (33), Gt(ROSA)26Sortm1(CAG-
Brainbow2.1)Cle/J (Confetti) (32), B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/J (ROSAmT/mG) (63), and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
were obtained from the Jackson Lab. K14-GFPactin mice (36) were a generous gift from 
Elaine Fuchs (Rockefeller University). B6.129(ICR)-Tg(CAG-ECFP)CK6Nagy/J (beta-
actin-CFP) mice (64) were a gift from Mikala Egeblad (Cold Spring Harbor Laboratory). 
For multicolor lineage tracing experiments, MMTVPyMT mice were crossed with ROSA 
mT/mG mice, Confetti mice, Rainbow mice, and beta-actin-CFP mice and transplanted 
into NSG host mice. For sorting of K14- and K14+ cells, MMTV-PyMT mice were crossed 
with K14-GFPactin mice. 
Isolation of Primary Mammary Tumor Organoids 
Primary tumor organoids were isolated from mammary tumors by step-wise mechanical 
disruption, enzymatic digestion, and differential centrifugation according to our published 
protocols (17, 20). Tumors were harvested from 8-10 week old mice, minced with a scalpel, 
and digested for 1hr at 37°C in collagenase solution: (D-MEM (10565–018; Gibco® Life 
Technologies) with 2 mg/ml collagenase (C2139; Sigma-Aldrich), 2 mg/ml trypsin 
(27250–018; Gibco® Life Technologies), 5% fetal bovine serum (FBS) (F0926; Sigma-
Aldrich), 5 μg/ml insulin (I9278; Sigma-Aldrich), and 50 μg/ml gentamicin (15750; 
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Gibco® Life Technologies). The suspension was centrifuged at 1500 rpm to remove 
cellular debris, and the pellet was treated with 2U/μL DNase (D4263; Sigma-Aldrich) to 
separate out organoids. Tumor organoids were separated from single cells by differential 
centrifugation and counted under a microscope. 
Mammary Fat Pad Transplantation 
Tumor organoids from MMTV-PyMT;ROSAmT/mG, MMTV-PyMT;Confetti, or 
MMTVPyMT;Rainbow were incubated with 1:50 adeno-CMV-Cre (1045; Vector 
BioLabs)/ D-MEM overnight in a non-adherent 96-well plate. Cre expression was induced 
successfully in more than 75% of the organoids. To wash out adeno-Cre, the samples were 
collected in a bovine serum albumin (BSA)-coated microcentrifuge tube and centrifuged 
at 1500 rpm for 10 mins. For intermediate mosaicism, tumor organoids were mixed 1:1 
with unrecombined tumor organoids. Tumor organoids were resuspended in a 50% D-
MEM/50% Matrigel (354230; Corning) solution at a density of 25–40 organoids/μl and 
kept at 4°C during transplantation. We conducted orthotopic transplantations into 3-4 week 
old NSG mice in a sterile hood. The mice were anesthetized with 2.5% isoflurane, 
immobilized and the surgical site was made sterile using ethanol. A 1cm midline incision 
was made, the skin was retracted, and the no. 4 mammary gland was exposed. The fat pad 
proximal to the lymph node was removed. Using a syringe, 40 μl of the tumor organoid 
suspension was injected into the mammary fat pad. The skin was then locally infiltrated 
with 5–10 μl of 0.25% bupivacaine. The same procedure was repeated for the contralateral 
mammary gland. The surgical wounds were closed using 9mm autoclips and tissue glue. 
Triple antibiotic ointment was applied to the incision. The mice were closely monitored, 
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and autoclips were removed 10 days post-surgery. Between 6-10 weeks, tumors and lungs 
from these mice were harvested. 
DIC Imaging and Confocal Microscopy 
Differential interference contrast (DIC) imaging of tumor organoids was conducted using 
a Zeiss Cell Observer system with a Zeiss AxioObserver Z1 and an AxioCam MRM 
camera (Carl Zeiss, Germany). Confocal imaging was conducted with a Zeiss 780 laser 
scanning confocal microscope (Carl Zeiss, Germany). 
Immunofluorescence Staining 
Tumors or lungs harvested from transplant mice were fixed in 4% or 1% paraformaldehyde 
respectively for 4 hours. They were then incubated in a 25% sucrose solution overnight, 
embedded in Tissue Tek® Optimal Cutting Temperature compound (O.C.T., Sakura) and 
frozen at -80°C. O.C.T. blocks were sectioned at 50 μm thickness using a Leica cryostat 
(Leica Biosystems, Germany) set to -27°C. For antibody staining, the O.C.T. was removed 
by rinsing with PBS for 45 minutes. Samples were blocked for 2 hours with 
10%FBS/1%BSA/PBS solution, incubated with the conjugated primary antibodies 
overnight at 4°C in 1%FBS/1%BSA/PBS solution, and rinsed two times in PBS for 10-20 
minutes. Slides were optically cleared, mounted, and sealed with coverslips. Primary 
antibodies used were: Alexa Fluor® Phalloidin (Life Technologies) anti-K14 (PRB-155P; 
Covance), anti-E-Cad (24E10; Cell Signaling Technologies) and DAPI (D3571; Life 
Technologies). To label functional vasculature, 10ug of anti-CD31 (102416; Biolegend) 
and anti-CD144 (138108; Biolegend) antibodies were injected into the mouse by tail vein 
(65). After 20 minutes, mice were sacrificed and tumors and lungs were collected. 
Isolation of CTCs 
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Approximately 500 μL of blood was harvested from each mouse via the right atrium using 
a 20G needle (305176; BD Biosciences) and 1mL syringe (309659; BD Biosciences). Prior 
to cardiac puncture, tumors were mechanically palpated to liberate CTCs into the systemic 
circulation, as in (7). Blood was transferred to 1mL K2EDTA tubes (365974; BD 
Biosciences) and placed on an inverter to prevent clotting. Blood was mixed 1:2 with ACK 
Lysis Buffer (118-156-721; Quality Biological) and centrifuged at 500G for 5 mins. The 
pellet was washed with 500uL PBS without Mg+2/Ca+2 (10010-023; Life Technologies) 
and centrifuged at 500G for an additional 5 mins. The pellet was resuspended in 450uL 
total volume with PBS without Mg+2/Ca+2 and spread onto slides with a proprietary 
adhesion coating (0906000, Marienfeld). Cells were left to settle on the slide for 5 mins. 
The slide was then incubated at 37°C for 60 mins. Slide supernatant was discarded and 
adherent cells were fixed with 4% PFA at room temperature for 30 mins. Slides were then 
washed with PBS without Mg+2/Ca+2 and permeabilized with 0.1% Triton-X at room 
temperature for 10 mins. Slides were again washed with PBS without Mg+2/Ca+2 and then 
blocked at 37°C for 20 mins. with an Fc receptor blocking antibody diluted 1:20 (101320, 
BioLegend) in 10% Normal Goat Serum (50062Z, Life Technologies). Slides were 
incubated with conjugated primary antibodies diluted in PBS without Mg+2/Ca+2 at 37°C 
for 1 hour. Antibodies used were pancytokeratin-AlexaFluor®488 (1:50; 4523S, Cell 
Signaling), Keratin 14-AlexaFluor®488 (1:250; PRB-155P, BioLegend), and CD45-
AlexaFluor®647(1:50; 103124, BioLegend). Slides were washed with PBS without 
Mg+2/Ca+2, mounted and coverslipped using ProLong Diamond Anti-Fade with DAPI 
(P36971, Life Technologies) and 24x60 coverglass (12-545-M, Fisher). Slides were left to 
dry overnight in a dark chamber and imaged on a Zeiss Axio Imager Z2 (Carl Zeiss 
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Microscopy, Germany) using Metafer 5 software (v3.11.3) (MetaSystems,Newton, MA). 
High resolution 3D images were collected on a Zeiss 780 laser scanning confocal 
microscope (Carl Zeiss Microscopy, Germany). 
FACS of Single K14- and K14+ Tumor Cells  
MMTV-PyMT; K14-actin-GFP were harvested for tumor organoids. Organoids were 
subsequently dissociated to single cell suspensions in StemPro® Accutase® Cell 
Dissociation Reagent (A11105-01; Life Technologies) for 20 minutes. Cells were then re-
suspended in HBSS/1%BSA. The resulting cell suspensions were filtered through 40 μm 
cell strainers and analyzed on a Beckman-Coulter MoFlo Cytometer by gating cellular 
distributions according to the eGFP reporter. Single cells and clusters were gated by FSLin 
vs Pulse Width. The nozzle size chosen for sorting was 100+ μm. Dead cells were excluded 
by propidium iodide fluorescence. For each condition, cells were sorted into 200 μL 
Matrigel and cultured in 24-well plates with D-MEM media supplemented with the growth 
factor basic human FGF (bFGF) (F0291; Sigma-Aldrich) at 37°C, 5%CO2. For the 
aggregation experiments, 10,000 single cells were sorted into D-MEM plus bFGF media 
and allowed to aggregate overnight in non-adherent well dishes at 37°C, 5%CO2. The 
samples were then re-suspended into 200 μL Matrigel and plated as mentioned above. The 
samples were fixed at day 8 for counting of colonies. To confirm aggregation, fractions of 
single cell suspensions were incubated for 1 hour with 10μM Cell Tracker Green and Cell 
Tracker Red (C7025 and C34552, Life Technologies), respectively, prior to sorting. An 
equal number of red and green cells where plated for a total of 10,000 single cells per well. 
Cell aggregates were analyzed the following day.  
Tail Vein Injections 
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NSG mice were injected with 200,000 single cells or an equivalent number of aggregated 
cells obtained from ROSAmT/mG;MMTV-PyMT or Beta-actin-CFP;MMTV-PyMT tumor 
cells isolated by FACS. Lungs from these mice were harvested 3 weeks later, and lung 
metastases were counted under the dissection scope or by counting metastases from 50 μm 
lung sections.  
Lentiviral Transduction of Tumor Organoids for Tumor Transplantation  
Lentiviral transduction of tumor organoids was conducted according to our published 
protocols (17). ~800 ROSAmT/mG;MMTV-PyMT organoids were resuspended in 100 μl 
of D-MEM/F12, and allowed to settle in a 96-well non-adherent dish for 1 hour at 37°C. 
The media was removed, and the organoids were infected with 50 μl of lentivirus 
(Mission® shRNA; Sigma-Aldrich) and 3 μl of ViroMag beads (VM4100; OZ 
Biosciences). The 96-well plate was incubated on top of a magnetic plate (MF10000; OZ 
Biosciences) at 37° C for 1.5 hours, then the magnetic plate was taken off and the 96-well 
plate was incubated overnight at 37°C. On day 2, 75 μl of media was removed and replaced 
with 200 μl of fresh FGF2 organoid media. On day 3, 175 μl of media was removed, and 
175 μl of FGF2 organoid media supplemented with 2.5 nM bFGF and 4 μg/ml puromycin 
was added. After 3 days, the surviving organoids were collected for orthotopic 
transplantation into the #4 mammary fat pads of FVB host mice. Tumor dimensions were 
measured at regular intervals (1-2 times a week) using digital vernier calipers. For analysis 
of disseminated tumor cell clusters, tumor-stroma border of primary tumor sections were 
scanned for dissemination events and confirmed to be completely detached from the 
primary tumor by sequential z-stacks. Dissemination events were scored as single cells or 
clusters (2 cells or more). 
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Estimation of Local Mixing in the Primary Tumor 
We took low-power montages of primary tumors in transplanted mice on a Zeiss 780 
confocal microscope. Fiji custom scripts were written to binarize these images and extract 
the percentage of pixels that were green in color (%Green). We then divided images into 
100x100 pixel grids (1.3mm x 1.3mm) and determined the probability of choosing two 
pixels of different colors in each grid. We defined %Local Mixing as two times the average 
probability of choosing two pixels of different colors averaged over all grids. Using robust 
linear regression, we then estimated the % of multicolored metastases at maximal local 
mixing for data in Figure 1E. 
High-throughput RNA Sequencing of K14- and K14+ Tumor Cells 
For each replicate, K14-actin-GFP;MMTV-PyMT tumor organoids were first dissociated 
into a single cell suspension, and then single K14- and K14+ cells were isolated by FACS. 
Four independent experiments were conducted. For each cell population, total RNA was 
extracted using TRizol (15596-026; Life Technologies) and RNeasy (QIAGEN). With 10-
100 ng of RNA collected per sample, we generated barcoded NuGen RNA-seq v.2 libraries 
and ran paired end, 100-bp, 50-cycle sequencing on a HiSeq 2000 (Johns Hopkins Medical 
Institutions Deep Sequencing and Microarray Core Facility). Paired-end, non-strand–
specific RNA-seq reads were mapped to the mouse reference genome (NCBI Build 37) 
using RNA-STAR version 2.3.0 (66). We achieved 80-85% read pair alignment to the 
reference genome and estimated the number of reads mapped to each gene using HTSeq 
version 0.6.1p1 (67), with gene coordinates from the reference genome Generic Feature 
Format file. Raw counts were normalized and p-values were calculated for paired sample 
differential expression using EdgeR (68). Genes were excluded which did not have at least 
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1 read per million in 4 of the 8 samples. This procedure yielded 12190 mapped genes, of 
which 11968 had gene annotation. Sequence data will be uploaded to the Sequence Read 
Archive. GO category enrichment was determined by DAVID Gene Set Analysis, version 
6.7, using the functional annotation chart algorithm, mouse genome as background, and 
goterm_bp_fat, goterm_cc_fat, and goterm_mf_fat gene lists (39). P-values for module 
enrichment were calculated using a Fisher exact test (1561 of 11968 genes with FDR 
<0.05).  
High-throughput RNA Sequencing of Luc-shRNA and K14-shRNA transduced 
tumor organoids 
For each replicate, MMTV-PyMT tumor organoids were transduced with luciferase control 
shRNA or K14 shRNA, and selected with puromycin as we have done previously (17). 
Transduced organoids were embedded in 3D Matrigel and after 2 days in culture, harvested 
for RNA. Four independent experiments were conducted. For each condition, total RNA 
was extracted using RNeasy (QIAGEN). With 10–100 ng of RNA collected per sample, 
we generated cDNA using the SMART-Seq v4 Ultra Low Input RNA Kit for sequencing 
(Clontech), barcoded libraries with the Nextera XT DNA Library Preparation kit 
(Illumina), and ran paired end, 100-bp, 50-cycle sequencing on a HiSeq 2500 (GE 
Healthcare Seqwright). Paired-end, non-strand–specific RNAseq reads were mapped to the 
mouse reference genome (Genomic Reference Consortium build 38) using RNA-STAR 
(66). We achieved 73-86% read pair alignment to the reference genome and estimated the 
number of reads mapped to each gene using HTSeq (67), with gene coordinates from the 
reference genome Generic Feature Format file. Raw counts were normalized and p-values 
were calculated for paired sample differential expression using limma and voom (69, 70). 
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Genes were excluded which did not have at least 1 read per million in 4 of the 8 samples. 
This procedure yielded 13332 mapped genes, of which 12919 had gene annotation. For 
each replicate (1 to 4), the knockdown efficiency was determined by dividing the Krt14 
transcript level in the K14- shRNA condition by the Krt14 transcript level in the Luc 
shRNA condition. A linear model was then fitted to the voomed expression data using a 
design matrix parameterizing batch effects and differences in knockdown efficiency 
between replicates. With this fitted model, genes were then ranked by p-value and FDR. 
The functional association network (Figure S7) was determined using the GeneMANIA 
web interface (71). 
Mammosphere assay 
For suspension mammosphere culture, MMTV-PyMT; K14-actin-GFP tumors were first 
dissociated into a single cell suspension, and then single K14 positive and K14 negative 
cells were isolated by FACS. Cells were plated on ultralow-adherence plates (Thermo 
Scientific) at 500 cells/cm2 and 1000 cells/cm2, respectively. Cells were culture in Basal 
Epicult-B mouse media (Stem Cell Technologies) containing B-supplement, 10ng/mL 
rhEGF, 10ng/mL rhbFGF, 4ug/mL heparin, and 1% penicillin/streptomycin. The number 
of spheres for each well was counted under the microscope on Day 7. The average number 
of spheres was compared across cell types and densities using the Mann Whitney test. 
Statistics 
Statistical analysis was conducted using the statistical program R or Graphpad Prism. For 
all boxplots, the whiskers represent the 5th and 95th percentiles. All tests used and P values 
are specified in the figure legends. P < 0.05 was considered significant.  
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Figure 3-1. Multicellular seeding is a frequent mechanism for distant metastasis.  
(A) Schema of multicolor lineage tracing assay. ROSAmT/mG;MMTV-PyMT tumor 
organoids were treated with  adenoviral Cre to induce recombination from  membrane 
tdTomato (mTomato) to membrane eGFP (mGFP). Mosaic  tumor organoids were then 
transplanted into  nonfluorescent NSG host  mice. After  6–8 wk, lungs  of these mice were 
harvested. If metastases arise exclusively from single-cell seeding, there should be  only 
single  color  metastases. In contrast, multicellular seeding should produce metastases with 
both colors.  (B) Representative micrographs of polyclonal lung  me- tastases of different 
sizes. n = 355 polyclonal metastases, across  16 mice and 4 independent experiments. (C) 
Representative micrograph of a mosaic  tumor organoid treated with adeno-Cre and grown 
in 3D Matrigel with  intermixing of red and green tumor cell clones. (D and E) 
Representative micrographs of primary tumors arising from  mosaic  tumor organoids 
transplanted into  NSG host mice. Primary  tumors varied in their local mixing  of red  and 
green tumor cell clones  (local mixing  %). These differences correlated with the percentage 
of multicolored metastases detected in the lung (% multicolored). n = 12 mice, 4 
independent experiments, 4,072 metastases. Correlation determined by Spearman rank  test 
for samples with  more than five lung  metastases per  mouse. (Scale bars,  20 μm in B and 







Figure 3-2. Direct observation of polyclonal collective invasion, polyclonal 
disseminated tumor emboli, and polyclonal CTC clusters.  
(A) Representative micro- graph of polyclonal collective invasion arising from mosaic 
ROSAmT/mG;MMTV-PyMT  transplanted  tumors stained with  phalloidin (F-actin)  and 
DAPI (n =75 units, 5 tumors). (B) Schema of two potential outcomes for disseminated 
tumor cell clusters at the tumor stromal interface. (C) Representative micrographs of a 
polyclonal disseminated tumor cluster (yellow arrow) in the x-y plane with successive 
images along the z axis (Left panels) and reconstructed 3D image (Right) (n = 25 units, 5 
tumors). (D) Representative micrograph of a polyclonal disseminated tumor embolus 
contained within a vessel. The transplanted tumor is composed of mTomato+ and CFP+   
tumor cells.  Injection with VE-Cadherin and CD31 fluorescently labeled antibodies 
marked functional vasculature. (E) Representative micrographs demonstrating E-
cadherin+ polyclonal collective invasion, dissemination, intravascular embolus (from left 
to right). Yellow hash marks:  vessel lumen. (F) Representative micrographs of CTC 
clusters composed of mTomato+ and CFP+ tumor cells and stained for K14 and DAPI (n 
= 1 multicolored cluster, n = 13 mTomato+ clusters, n = 2 CFP+ cluster). (G) The number 
of events for each CTC cluster size is presented as a histogram (n = 134 events, 3 
transplanted mice). (H) The median percentage of cells that are K14+ in CTCs of different 
cluster sizes are presented as a boxplot (n = 17 clusters). [Scale bars, 2 mm (A, Left), 40 















Figure 3-5. The transcriptional program of K14+ tumor cells is enriched for 
desmosome and hemidesmosome adhesion complex genes, and depleted for genes 
involved in MHC class II immunosurveillance. 
(A) K14- and K14+ cells were isolated by FACS from K14-actin-GFP;MMTV-PyMT 
tumors and the relative mRNA expression of K14 relative to GAPDH was determined by 
quantitative RTPCR. The relative mRNA expression is presented as a boxplot (N=4 
independent experiments). P-value determined by Wilcoxon rank sum test. (B) Heatmap 
of the most differentially expressed genes determined by RNA sequencing of K14- and 
K14+ cells at a genome-wide significance of P < 10-6. (C-C’) Genes that encode for 
desmosome, hemidesmosome, and MHC class II antigen presentation protein complexes 













Supplemental Figure 3-1. Lineage tracing in Confetti and Rainbow mice identify 
multicolored lung metastases in the MMTV-PyMT model.  
(A, Left) Schema of multicolor lineage-tracing assay to determine clonality of metastases 
using the Confetti reporter. Confetti;MMTV-PyMT tumor organoids were treated with 
adeno-Cre to induce recombination to one of four colors: nuclear-GFP, membrane CFP, 
cytoplasmic YFP, or cytoplasmic RFP. Mosaic tumor organoids were then transplanted 
into nonfluorescent NSG host mice. After 6–8 wk, the lungs were harvested, and the 
number of multicolored lung metastases was counted. (Right) Representative Adeno-Cre 
treated Confetti tumor organoid grown in 3D Matrigel. (B, Left) Representative 
micrograph of no-color dominance in a transplanted Confetti;MMTV-PyMT tumor stained 
with phalloidin (F-actin) and DAPI. (Lower) Inset of region denoted by star in Upper panel, 
showing solid boundary between RFP+ and no-colored cells. (Right) Median percentage 
area of the primary tumor occupied by no-color tumor cells presented as a dot plot (n = 30 
tumors, 15 mice, 3 independent experiments). (C, Left) Representative multicolored lung 
metastasis in a transplanted Confetti;MMTV-PyMT mouse. Lung sections were stained 
with phalloidin (F-actin) and DAPI. (Right) Bar graph of color distribution of lung 
metastases (n = 11 metastases, 2 mice). (D, Left) Schema of multicolor lineage-tracing 
assay to determine clonality of metastases using the Rainbow reporter. Rainbow; MMTV-
PyMT tumor organoids were treated with adeno-Cre to induce recombination to 1 of 21 
potential colors. Mosaic tumor organoids were then transplanted into nonfluorescent NSG 
host mice. After 6-8 wk, the lungs were harvested and the number of multicolored lung 
metastases were counted. (Right) representative Adeno-Cre treated Rainbow tumor 
organoid grown in 3D Matrigel. (E, Left) Representative micrograph of no-color 
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dominance in Rainbow;MMTV-PyMT transplanted tumor stained with phalloidin (F-actin) 
and DAPI. (Lower) Inset of region marked with star in Upper panel, showing solid 
boundary between RFP+ and no-colored cells. (Right) Median percentage area of the 
primary tumor occupied by no-color tumor cells presented as a dot plot (n = 26 tumors, 13 
mice, 2 independent experiments). (F, Left) Representative multicolored lung metastasis 
identified in a Rainbow;MMTV-PyMT transplanted mouse. Lung sections were stained 
with phalloidin (F-actin) and DAPI. (Right) Bar graph of color distribution of lung 
metastases (n = 83 metastases, 6 mice, 2 independent experiments). [Scale bars, 50 μm (A, 
B, Lower, D, E, Lower), 2 mm (B, Upper, and E, Upper), and 100 μm (C and F).] 
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Supplemental Figure 3-1.  
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Supplemental Figure 3-2. Polyclonal metastases arise from multicellular seeds not by 
serial seeding of single tumor cells.  
(A) Schema of transplant assay to model the contribution of serial seeding to polyclonal 
metastases. mTomato+ tumor organoids were isolated from ROSAmT/mG;MMTV-PyMT 
tumors and transplanted to the right flank of a nonfluorescent NSG mouse. Tumor 
organoids were isolated from β-actin-CFP;MMTV-PyMT tumors and transplanted to the 
left flank of the same mouse. After 6-8 wk, lungs of these mice were harvested and 
examined for multicolor metastases. There are two potential outcomes at the metastatic 
site. If metastases arise exclusively from a single seeding event, there should be only 
single-color metastases. In contrast, serial seeding by single cells should produce 
multicolored metastases. (B) Representative micrograph of transplanted tumors arising 
from either mTomato+ or CFP+ tumor organoids transplanted into NSG host mice (n = 22 
tumors, 11 mice, 2 independent experiments). mTomato+ tumor cells were observed in 5 
of 11 CFP+ tumors and accounted for 1–5% of the total tumor area. (C and C′) 
Representative micrographs of CFP+ tumor colonized by a large mTomato+ metastasis (C) 
and a small mTomato+ tumor cell cluster (C′). The tumor was stained with phalloidin (F-
actin) and DAPI. (D) Representative micrographs of single colored CFP+ or mTomato+ 
lung metastases. Multicolored metastases were not observed (n = 0 of 75 metastases, 7 
mice, 2 independent experiments). (E) Schema of tail vein assay that models serial waves 
of disseminated single tumor cells. 2 Å~ 105 FACS-sorted mTomato+ single cells were 
injected into nonfluorescent NSG host mice and 2 d later, 2 Å~ 105 FACSsorted CFP+ 
single cells were injected into the same mice. Three weeks later, lungs were collected and 
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analyzed. Multicolored metastases were not observed (n = 0 of 64 metastases, 4 mice). 
(Scale bars, 1 mm in B, 500 μm in C, 1 mm in C′, and 50 μm in D.) 
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Supplemental Figure 3-3. Multicolored disseminated tumor emboli are observed.  
(A) Representative micrograph of a multicolored disseminated tumor cell cluster invading 
into an adjacent vessel. The transplanted tumor is composed of mTomato+ and CFP+ tumor 
cells. Injection with fluorescently labeled VE-Cadherin and CD31 antibodies marked 
functional vasculature. Tumors were also stained with DAPI to mark nuclei. Leftmost 
panel demonstrates a collective cluster (cc) of tumor cells invading into a nearby vessel 
lumen (L). Inset shows CFP+ blebs in close proximity to the vessel (n = 12 units, 6 tumors). 
(B) Representative micrographs of multicolored disseminated tumor cell cluster 
intercalated into adjacent blood vessel wall. A mosaic mTomato+, CFP+ tumor was stained 
with DAPI. The mouse was injected with fluorescent VE-Cadherin + CD31 antibodies 
before sacrifice. White hash marks: vessel lumen. Magenta harsh marks: cell cluster. (C) 
Representative micrographs demonstrating intercalation of disseminated tumor cell 
clusters into vessels of varying caliber. Mosaic MMTV-PyMT;mT/mG ;MMTVPyMT 
transplanted tumors were stained with phalloidin (F-actin) and DAPI. Yellow hash marks: 
vessel lumen. (D) Representative micrographs demonstrating intravascular dissemination 
units of different sizes in vessels adjacent to primary tumor. Mosaic MMTV-
PyMT;mT/mG transplanted tumors were stained with phalloidin (F-actin) and DAPI. 













Supplemental Figure 3-5. Disseminated tumor cells are enriched for K14+ and FACS-
sorted single K14+ and K14− tumor cells Interconvert to form uniformly K14+ 
clusters. 
(A) Representative micrographs demonstrating K14+ polyclonal collective invasion, 
dissemination, and intravascular embolus (from left to right). Mosaic 
ROSAmT/mG;MMTV-PyMT transplanted tumors were stained with DAPI and K14. 
Yellow hash marks: vessel lumen. (B) The percentage of disseminated single tumor cells 
and disseminated tumor cell clusters that are K14+ presented as a bar-graph (n = 45 single 
cells, n = 17 clusters, across 5 tumors). P value determined by Fisher’s exact test. (C) Single 
K14+ and K14− tumor cells were isolated by FACS from K14-actin-GFP;MMTV-PyMT 
tumors, and then subsequently stained for K14, phalloidin (F-Actin), and DAPI. (Right) 
The median intensity of K14 staining for each cell presented as a boxplot (n = 317 cells, 3 
independent experiments). P value determined by Mann–Whitney test. (D, Left) Cell 
clusters formed at day 1 postaggregation were stained for K14, DAPI, and phalloidin (F-
actin). (Right) Bar graph shows the percentage of clusters composed of only K14− cells, 
only K14+ cells, or both cell types (n = 119 clusters, 3 independent experiments). (E, Left) 
Colonies formed at day 8 were stained for K14 and phalloidin (F-actin). (Right) Bar graph 
shows the percentage of colonies composed of only K14− cells, only K14+ cells, or both 
cell types (>10 cells per colony, n = 55 colonies, 3 independent experiments). (Scale bars, 
10 μm in A, Center, C, and D; 20 μm in A, Left and Right, and E.) 
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Supplemental Figure 3-6. K14+ cells and K14− cells are enriched for different 
stemness genes and are not significantly different in their mammosphere forming 
ability. 
(A) Relative expression of different stem cell-associated genes presented as a dot-plot. P-
value determined by Mann–Whitney test. (B) Enrichment in K14+ and K14− cells was 
determined by Wilcoxon gene set testing using published stem cell gene sets identified by 
transcriptome profiling of mouse mammary gland. (C) Representative micrographs of 
mammospheres generated from K14− and K14+ single cells in suspension culture. (Scale 
bars, 100 μm.) (D) The median number of mammospheres is presented as a dot plot for 
K14− and K14+ single tumor cells isolated by FACS and plated at two different densities. 
P value determined by the Mann–Whitney test. 
  
 114 




Supplemental Figure 3-7. Gene network of K14+ metastasis genes. The network of 
coregulated genes seeded using the most differentially expressed genes in Fig. 6E. Seed 
genes in black, neighbor genes in gray. Physical interactions, genetic interactions, and 





Supplemental Figure 3-8. Polyclonal metastasis occurs through collective 
dissemination of K14+ tumor cell clusters. Primary tumors invade and disseminate 
collectively into surrounding tissue. This disseminated unit efficiently colonizes distant 
sites to form polyclonal metastasis. In MMTV-PyMT tumors, the traveling unit is 
composed of multiple K14+ epithelial tumor cells. Our model is supported by multiple 
lines of experiments in our study: the high frequency of multicolored metastases arising 
from well mixed multicolored primary tumors in which clonality can most readily be 
assessed (Fig. 1 and Fig. S1), the lack of multicolored metastases when the different 
colored cells are deployed at different locations or at different times (Fig. S2), the 
observation of polyclonal clusters across major stages of metastasis (Fig. 2), the large 
survival advantage conferred by multicellular organization both in culture and in vivo (Fig. 
3), the enrichment for K14 expression in disseminated tumor cells and micrometastases 
(Fig. 4), the expression of epithelial desmosome and hemidesmosome gene programs in 
K14+ cells (Fig. 5), and the requirement for K14 expression for both distant metastasis and 
the expression of multiple metastasis effectors, crucial for remodeling of the metastatic 
niche, including Tnc, Adamts1, Jag1, and Ereg (Fig. 6). 
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An engineered 3D vessel model reveals the dynamics of  




In a solid tumor, vascular structure and function varies from the core to the periphery and 
this heterogeneity can influence the mechanisms employed by tumor cells to enter 
circulation. In the core, blood vessels can have defects in endothelial coverage, leaving 
cancer cells directly exposed to flow and potentially promoting intravasation. Consistent 
with prior reports, we observed that approximately 6% of vessels in a mouse model of 
breast cancer exhibited a mosaic morphology in vivo. The mechanisms by which mosaic 
vessels form remain incompletely understood, in part because of the challenges associated 
with observing tumor-vessel interactions deep within tumors in real-time. To overcome 
this challenge, we developed a tissue engineered tumor model which contains a 
physiologically and morphologically realistic microvessel in co-culture with mammary 
tumor organoids. This approach allows real-time and quantitative assessment of tumor-
vessel interactions under conditions that recapitulate many in vivo features. We observed 
mosaic vessel formation in real-time and found that it was the most frequent type of tumor-
vessel interaction in vitro compared to vessel constriction and vessel pull. Moreover, our 
model reveals that tumor cells invade the vessel wall by integrating with the endothelial 
cell lining, suggesting the formation of a tumor-endothelial cell junction. Furthermore, we 
observed in real-time an intravasation event that followed the formation of a mosaic vessel. 
Our assay enables future studies that could reveal mechanisms to target mosaic vessel 




Metastasis is responsible for approximately 90% of cancer patient mortality (1, 2). Cancer 
progression is a highly dynamic multi-step process, by which cancer cells escape the 
primary tumor, intravasate, circulate, seed distant sites, and form secondary tumors. The 
initial steps in cancer metastasis involve the invasion of tumors cells into the surrounding 
stroma and intravasation into the vasculature. Single circulating tumor cells (CTCs) and 
circulating tumor microemboli (CTM) have been detected in circulation in mouse models 
as well as cancer patients (3, 4). Furthermore, though rare, CTM have been shown to have 
a higher metastatic potential compared to single tumor cells (5, 6). However, the 
mechanisms of tumor-vessel interactions that enable tumor cell entry into circulation are 
poorly understood (7).  
 
Intravasation is an early step in the metastatic cascade and is accomplished when cancer 
cells gain access to circulation (8, 9). Intravital imaging within primary tumors has offered 
insights into intravasation by revealing single cancer cells migrating into vessels, in a 
process termed transendothelial migration (TEM, 10). However, as solid tumors grow, they 
expand beyond the capacity of pre-existing vessels and develop their own vascular supply 
(10-12).  These newly formed vessels are diverse in their structure and permeability 
(“leakiness”), and vary from the tumor core to its periphery (12-14). These changes could 
enable alternate mechanisms or rates of intravasation. The recent emphasis on collective 
dissemination and metastasis of CTMs (5, 6, 15, 16), has raised new questions about how 
groups of adherent cells could access the circulation. 
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Most of our understanding of tumor-vessel structure and function has been derived from 
static images of fixed tissues. Structural studies have revealed tumor vessels with defective 
organization and loosely connected endothelial cells (17). Immunohistological sections of 
varying primary tumor xenografts from different mice and human tumor cell lines have 
revealed that tumor vasculature exhibits intercellular openings up to 4.7 μm in size 
allowing the local extravasation of both drug delivery systems and red blood cells, a 
phenomenon known as the enhanced permeation and retention (EPR) effect (17, 18).  In 
addition to intercellular gaps, tumor vasculature in colon carcinoma xenografts has been 
shown to exhibit a hybrid structure, with both tumor cells and endothelial cells contributing 
to the vessel wall (termed “mosaic vessels”) (19, 20). This loss of endothelial coverage 
presents a mechanism by which tumor cells could access the circulation without the need 
for TEM (19).  
 
Despite these intriguing observations very little is known about the dynamics of tumor-
vessel interactions and their effect on intravasation. To approach this problem, we 
developed a 3D tissue-engineered model of the tumor microenvironment in which we co-
cultured primary tumor organoids with functional microvessels and visualized the cellular 
interactions in real time (21). This microfluidic approach enabled us to observe three 
different types of tumor-vessel interactions: mosaic vessels, vessel constriction, and vessel 
pull. We found that mosaic vessels formed rapidly and were the most frequent type of 
interactions observed in vitro. Moreover, we observed mosaic vessel formation in real-time 
leading to collective intravasation of CTMs. Although rare, we observed vascular 
constriction due to engulfment by a growing organoid that can contribute to the formation 
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of vascular defects such as dead-ends.   In addition, we observed organoids “pulling” on 
microvessels, termed vessel pull, which could be a mechanism for vessel co-option by 
highly adherent tumor cells. We found an increase in endothelial cell proliferation and cell 
death in the presence of tumor organoids within the microvessels which can influence the 
type of tumor-vessel interaction that will be formed, and, consequently, the mechanism by 




Primary tumors are exposed to the lumen of vessels partially lined with endothelial 
cells in vivo 
To establish the prevalence of mosaic vessels, we first sought to characterize their 
frequency in a commonly used and highly metastatic mouse model of breast cancer, in 
which the MMTV LTR is used to drive the polyoma virus middle T oncogene (22).  We 
crossed this cancer model with a fluorescent reporter mouse in which all cells are labeled 
with a membrane localized red fluorescence protein (mTomato) (23). To unambiguously 
identify tumor tissue in contact with the lumen of mosaic blood vessels, we performed 
orthotopic transplants of ROSAmTmG; MMTV-PyMT tumor organoids into non-fluorescent 
NSG host mice. We assayed for mosaic vessels by staining for platelet-endothelial cell 
adhesion molecule (PECAM-1/CD31, green) with immunofluorescence, and scanned the 
entire sections (16 µm total tissue depth) in 1 µm steps. Microvessels were considered for 
analysis if they intersected the tissue section with an approximately circular cross-section 
(i.e. orthogonal to the tissue section). We defined potential mosaic vessels by the presence 
of tumor cells in apparent contact with the vessel lumen in 2D, as indicated by the absence 
of CD31 staining (Fig 1AB). We then confirmed the mosaic vessel structure in 3D optical 
reconstructions (Fig. 1 DE). This method ensured that we did not miss-classify vessels due 
to variations in staining or loss of cell fragments during preparation of the tissue sections.  
We also assessed the completeness of the endothelial lining based on differences in nuclei 
morphology (DAPI staining, blue) between tumors and endothelial cells. Tumor nuclei 
appeared more rounded compared to the elongated shape of endothelial nuclei. Based on 
these criteria, mosaic vessels could be readily distinguished from intact vessels in these 3D 
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volumes (Fig 1B' vs. C'). In total, we examined 2681 vessels in 20 whole tissue sections 
from three tumors derived from independent transplant mice and identified 168 mosaic 
vessels (6.3%). The average luminal vessel diameter was 103 ± 50 µm. While we did not 
have sufficient sections for quantitative analysis of the spatial distribution, we observed 
that mosaic vessels were generally located close to the core of the tumor with none at the 
periphery.  
 
A perfusable 3D tissue-engineered microvessel platform for examining mosaic vessel 
formation 
We next sought to understand the cellular dynamics underlying mosaic vessel 
formation. To accomplish this goal, we developed a tissue engineered model for real-time 
imaging of tumor-vessel interactions (21, 26). The goal was to build a functional 
microvessel surrounded by tumor organoids from the ROSAmTmG; MMTV-PyMT model 
(Fig. 2A). The microvessel platform consists of a cylindrical channel lined with a confluent 
monolayer of endothelial cells. Initially, the tumor organoids were embedded in a collagen 
type I matrix within a PDMS housing surrounding a central metal rod which provides a 
template for the vessel (Fig. 2B). The rod was then removed leaving behind a cylindrical 
channel that was seeded with endothelial cells, which were allowed to settle and adhere to 
the channel walls to form an intact vessel (Fig 2B). The vessel was then perfused with 
endothelial cell medium at a physiologically relevant shear stress and a steady laminar 
flow. The microvessels were generated using GFP expressing human umbilical vein 
endothelial cells (HUVEC-GFP).  
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For direct visualization of tumor-vessel interactions, we typically imaged at the mid 
plane of the vessel (Fig. 2C). Immunofluorescent staining for b-catenin revealed a 
complete lining of endothelial cells, arranged in a cylindrical geometry and with extensive 
intercellular adhesions (Fig. 2D). The tissue-engineered microvessels contained a single 
intact lumen, as demonstrated by the mid-plane and cross-section images (Fig. 2D). Barrier 
function was verified by measurement of the permeability of fluorescent probes introduced 
into the lumen. Tumor organoids were cultured in close proximity to the microvessel (Fig. 
2E, F) and exhibited a 3-fold increase in area over three days of culture with constant vessel 
perfusion, consistent with survival and extensive proliferation (Supplemental Fig. 1H, I). 
Co-cultures require that media conditions are acceptable to all cell types. Accordingly, we 
compared the growth of organoids isolated from the same mouse in three different media 
conditions: “organoid medium” supplemented with FGF2 (16, 25), HUVEC medium, and 
HUVEC medium supplemented with dibutyryl-cAMP (db-cAMP; Supplemental Fig. 1A-
G). We used cAMP as a means to verify vessel integrity and function (30, 31). Tumor 
organoid growth and circularity were determined by measuring the projected surface area 
at day 0 and day 5 in the microvessel model. We observed a significant increase in growth 
and circularity of tumor organoids compared to control in all media conditions 
(Supplemental Fig. 1F-G). In addition, organoids in HUVEC media exhibited a more cystic 





Co-culture with tumor organoids increases vessel permeability and induces transient 
focal leaks 
We first sought to determine the functional properties of the tissue-engineered 
microvessels in the presence and absence of tumor organoids. Endothelium integrity and 
barrier function were determined by measuring permeability (P3D, cm s-1), which describes 
the rate of transport of a solute from the vessel lumen across the endothelium and into the 
surrounding ECM (26, 29). We measured vessel permeability by simultaneously perfusing 
three different fluorescent molecular weight probes through the vessel lumen: 3 kDa 
dextran (Alexa Flour-488-conjugated), 10 kDa dextran (Alexa Flour-647-conjugated) and 
70 kDa dextran (Texas Red). Using three different size probes enabled assessment of the 
size of defects in the endothelium. From time-lapse fluorescence microscopy we identified 
the time prior to the arrival of the fluorescent probe (designated 0 min; Fig 3A-D), luminal 
filling (typically 20 min, Fig 3A'-D'), and the kinetics with which the fluorescence probes 
perfused out of the vessel and into the ECM (Fig 3A''-D''). For all three molecular weight 
dextrans, co-culture with tumor organoids increased vessel permeability by about 10-fold 
to 3 – 6 x 10-5 cm s-1 (Fig. 3E, Supplemental Fig. 3E, C). There was not statistical difference 
between the permeabilities for 3 kDa, 10 kDa, and 70 kDa dextrans showing that the defects 
in the endothelium were sufficiently large to allow extravasation of relatively large 
molecules: the diameter of 70 kDa dextran is approximately 12 nm (32). In contrast, 
treatment with 400 µM dibutyryl-cAMP (db-cAMP) decreased permeability in both control 
and tumor co-culture microvessels (Fig. 3B-B'', D-D'', E, Supplemental Fig. 2). We also 
found that luminal filling is delayed in vessels treated with db-cAMP suggesting a tighter 
barrier function. 
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Our dynamic imaging of vessel permeability also revealed transient focal leaks of 
labeled dextrans (Fig. 3F-H). To unambiguously identify regions of excess fluorescence 
intensity along the length of the microvessels, we used the 10 kDa dextran (Alexa Flour-
647-conjugated) probe. We observed a higher number of focal leaks in co-cultures with 
tumor organoids and, conversely, a reduced number of focal leaks in both control and 
tumor co-culture microvessels following treatment with db-cAMP (Fig. 3G). In addition to 
the increase in vessel permeability in the presence of tumor organoids, we found a positive 
correlation with the increase in number of focal leaks (Fig. 3H). Consistent with our results, 
transient focal leaks have been detected in the tumor vasculature of mouse brains and 
mammary glands (33-35) and cAMP agonists have previously been shown to suppress 
focal leaks and decrease the macromolecular permeability coefficients (30, 31).  
 
Tumor organoids actively replace the endothelial lining to form mosaic vessels 
Having established that our tissue-engineered microvessels were functional and 
that their permeability was regulated by co-culture with tumor organoids, we next sought 
to analyze the cellular basis of tumor-vessel interactions in real time. To accomplish this 
goal, we co-cultured ROSAmTmG; MMTV-PyMT organoids within the ECM of our 
microvessel model. We used wide-field fluorescence microscopy, focused on the mid plane 
of the vessel, to follow cell behaviors (Fig. 1C). We observed three different types of 
tumor-vessel interactions: (1) cancer cells integrating with the endothelial lining to form 
mosaic vessels (Fig. 4A-A'), (2) cancer cells wrapping around the vessel and constricting 
the lumen (Fig. 4B-B'), or (3) cancer cells pulling on the microvessel and displacing its 
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position (Fig. 4C-C'). The geometry of each type of tumor-vessel interaction was confirmed 
in cross-section (Fig. 4A'-C').  
 
For quantification purposes, we identified mosaic vessels using two criteria: (i) 
clear visible retention of fluorescent dye at the site of tumor-vessel contact, and (ii) no 
interruption of flow following tumor-vessel interactions. In contrast, vessel constriction 
resulted in diminished or abolished downstream flow. Quantification of 19 devices 
revealed that mosaic vessel formation was the most frequent type of tumor-vessel 
interaction (Fig. 4G). We next tested the functional status of the mosaic vessels from 
measurements of solute permeability. We observed dye retention in the lumens of the 
vessels at the sites of tumor-endothelial cell contact, revealing that the cancer cells 
contributed to barrier function (Fig. 4D-F, D'-F'). 
 
Mosaic vessels as a route for intravasation of tumor cells 
The presence of tumor cells in the vessel lining exposes them directly to flow and 
represents a potential mechanism for intravasation. Once mosaic vessels are formed, 
individual CTCs or CTMs can be released into circulation. We next assayed for 
intravasation in mosaic regions along the microvessel. As above, we visualized tumor-
vessel interactions using wide-field fluorescence microscopy focused at the mid-plane of 
the microvessel (Fig. 5A-B). We observed an organoid approaching a microvessel, making 
contact with and incorporating into the endothelium, then releasing a tumor microemboli 
into circulation (Fig. 5A'-B'). The tumor microemboli appears to roll on the luminal side 
of the endothelium as it moved in the direction of flow (Fig. 5A'-B').  
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A perfusable 3D microvessel platform for modeling mosaic vessel formation 
We next sought to design a microvessel platform that would enable reproducible 
placement of tumor cells relative to the engineered microvessel. In our previous model, 
tumor organoids were seeded randomly throughout the collagen matrix and the likelihood 
of interacting with the vessel was dependent on the initial location of the organoids. To fix 
the distance between the tumor organoid and the microvessel, we introduced a modification 
in the microfluidic platform. A second cylindrical template channel was introduced within 
the PDMS housing parallel to the first microvessel channel (Fig. 6A-B). Once the two 
template rods were placed into the PDMS housing, the collagen solution was introduced 
and allowed to gel. We first introduced the tumor organoids into one of the channels by 
slowly removing one rod leaving the other in place. The second cylindrical rod was then 
removed following the steps previously described for vessel formation. Using wide-field 
fluorescence microscopy focused at the mid-plane of the microvessel (Fig. 6C), we 
observed tumor invasive strands initiate and grow in the direction of the vessel 
incorporating into the endothelial lining (Fig. 6D-E).  
 
Endothelial proliferation and cell death in response to tumor organoids  
To analyze the influence of tumor organoids on the endothelium, we quantified 
endothelial cell proliferation and cell death. We measured the frequency of cell 
proliferation and cell death within the microvessels using time-lapse phase-contrast 
microscopy imaging focused at the vessel poles (i.e., top and bottom) (Supplemental Fig. 
3A). Endothelial cell divisions were visualized by the increase in cell’s light refraction and 
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cell rounding followed by the integration of the two daughter cells back into the 
endothelium (Supplemental Fig. 3B). The proliferation rate was calculated as the 
percentage of endothelial cells dividing per hour (%/h). We found that tumor organoids 
increased endothelial cell proliferation by approximately 2-fold compared to control. In 
contrast, treatment with 400 µM db-cAMP decreased endothelial cell proliferation in both 
control and tumor co-culture microvessels (Supplemental Fig. 3C). Similarly, cell death 
was observed by the pronounced cell contraction and removal from the endothelium in the 
direction of flow (Supplemental Fig. 3D). We found that tumor organoids increased cell 
death by 4-fold compared to control and decreased upon treatment with db-cAMP 
(Supplemental Fig. 3E).  Based on these results, we found that the net change in the number 
of endothelial cells was -1.3 %/h in the presence of tumor organoids. In particular, the 
negative sign in the net change demonstrates that endothelial turnover is dominated by cell 





The goal of this work was to study the cellular dynamics of tumor-vessel 
interactions using a 3D microvessel model of the tumor microenvironment combined with 
3D organotypic culture of a highly metastatic breast cancer model. While the initial steps 
in the metastatic cascade involve interactions of cancer cells with blood vessels, little is 
known about the dynamics of this process. Prior studies have reported a vast heterogeneity 
in tumor vessel architecture ranging from intact endothelium to complex network structures 
(19, 36). Furthermore, tumor-vessel heterogeneity has been shown to vary from the 
periphery to the tumor core. Typically, tumor vessels are found to be intact in the periphery, 
however, the tumor core presents a range of vascular abnormalities including loops, dead-
ends, partial (i.e., mosaic vessels), or an absence of endothelial cell lining (i.e., 
vasculogenic mimicry), among other defects (13, 37). The range of these defects can dictate 
the mode and frequency of CTCs and CTMs entering circulation. Irregularities in 
endothelial cell coverage have been suggested to have important implications in 
intravasation. Studies of fixed tissue sections have shown the presence of tumor cells 
within the vessel wall in many cancer types; however, the dynamics of this process has not 
been studied. This challenging task has been hindered due to the difficulties in establishing 
tumor models in which tumor-vessel interactions can be visualized and characterized.  
 
To study the cellular dynamics of tumor-vessel interactions used a 3D tumor-
microvessel model that incorporates a functional vasculature within an extracellular matrix 
material. This reductive model combines a perfusable microvessel with freshly isolated 
mammary gland tumor organoids embedded in the surrounding matrix (21). In this way, 
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we recapitulated both the microvessel cylindrical geometry, endothelium-matrix 
interactions, and shear stress and flow, along with the 3D structure of tumors (Fig. 2) (25). 
This approach enables visualization of tumor-vessel interactions in real time, recapitulating 
many aspects of the spatial organization and structure of the in vivo microenvironment.  
 
From extensive imaging, we observed three types of tumor-vessel interactions: 
mosaic vessels, vessel constrictions, and vessel pull (Fig. 4 and Fig. 7B). We found that 
mosaic vessels were the most frequent type of tumor-vessel interactions observed in vitro. 
Interestingly, in patient biopsy samples from varying malignancies, such as glioblastoma, 
melanoma, gastric cancers and sarcomas, the partial or complete absence of endothelial 
cell lining has been associated with distant metastasis and poor patient survival (38-40). 
The presence of tumor cells in vessel walls has been suggested as a mechanism for bulk 
and high rate intravasation events since it gives tumor cells greater access to systemic 
circulation. However, the mechanisms of formation of vascular defects and subsequent 
intravasation remain poorly understood. Using our tumor organoid-microvessel platform, 
we show for the first time the formation of mosaic vessels in real time (Fig. 4). 
 
Following mosaic vessel formation, we observed the detachment of CTMs that 
rolled on the luminal side of the endothelium in the direction of the vessel flow. Previous 
animal and clinical studies have shown that CTCs and CTMs can be shed into the 
circulation during tumor resection and, consequently, soft tumor manipulation decreased 
the risk of metastatic lesions (41-44). Recent studies in mice have demonstrated that CTMs, 
as opposed to CTCs, have increase survival and higher metastatic potential (5, 6, 15, 16).  
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CTMs are thought to originate from clusters of polyclonal cells arising directly from the 
primary tumor and not by aggregation of CTCs in circulation (5, 6), however, the 
mechanisms by which CTMs gain access to the systemic circulation remain unknown. 
Using our tumor-microvessel model, we show a mechanism for CTM intravasation at 
mosaic vessels that bypasses the need for TEM. 
 
Additionally, the size of the CTMs entering circulation has been suggested to be 
regulated by vessel diameter (45). Our results show a CTM of 50 µm in diameter that 
detached from a microvessel of approximately 150 µm in diameter. Moreover, our in vivo 
analysis showed an average mosaic vessel diameter of approximately 100 µm. Our results 
are in line with observations in brain tumors where vascular invasion was more prevalent 
in vessels >200 µm in diameter which correlated with increased risk of metastasis and poor 
patient survival (45).  
 
In addition to mosaic vessel formation, we observed, vascular constriction and 
vessel pull.  Previous work has shown that tumors induce a mechanical stress on nearby 
vessels due to an uncontrolled growth within a confined space (46, 47). Here, we suggest 
vascular constriction as a mechanism for the formation of vascular defects such us dead-
ends. Furthermore, vascular constriction can generate hypoxic regions that may increase 
the imbalance in pro- and anti- angiogenic signals further increasing tumor vascularization. 
We also observed tumors pulling on the vessel wall which may indicate sites of vessel co-
option (i.e., the use of pre-existing vessels) by adherent tumor cells (21). For example, 
brain metastatic lesions from human melanoma cell lines have been shown to use vessel 
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co-option as a mechanism to obtain nutrients without the need of an angiogenic switch 
which has high implications on anti-angiogenic therapies (48). This type of tumor-vessel 
interaction has been confirmed in fixed tissue section of brain biopsies from cancer patients 
(48). 
 
Our tumor-microvessel model recapitulates many aspects of the intratumoral 
vasculature which lacks many of the features of healthy vasculature, such as smooth muscle 
cells and pericyte coverage, and poor lymphatic drainage. Tumor vasculature is leakier 
than normal vasculature, termed the enhanced permeation and retention (EPR) effect. This 
effect is widely exploited in systemic delivery of therapeutic agents to solid tumors.  Here 
we show an approximately 10-fold increase in permeability of 3, 10 and 70 kDa dextrans 
in organoid-containing microvessel models, recapitulating the increase in leakiness 
associated with the EPR effect (49).  In addition, the measured permeabilities of the three 
dextrans are not statistically different, as expected for paracellular transport at vascular 
defects (18, 50).  In xenograft mouse models, the EPR effect results in extravasation of 
large particles into the tumor (51).  The cutoff size is typically between 0.2 - 1 µm in 
diameter, depending on the tumor type. 70 kDa dextran, the largest solute used here (12 
nm diameter), is within this cut-off range (32). 
 
Until now, tumor-vessel interactions have been mostly studied using fixed tissue 
sections. Here we showed the dynamics of tumor-vessel interactions using a 3D 
microvessel model along with 3D organotypic culture of primary breast cancer tissue. We 
were able to model three types of interactions: mosaic vessel, vessel constriction and vessel 
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pull, each of which may have important implications for cancer metastasis (Fig. 7A-B). 
Tumors that generate sufficient force on the endothelium to disrupt cell-cell junctions can 
enable the formation of mosaic vessel structures facilitating shedding of CTCs and/or 
CTMs exposed to the vessel flow and shear forces, without the need of TEM. While vessel 
constriction may give rise to other vascular defects such as dead-ends, vessel pull could be 
a mechanism used by highly adherent tumor cells to co-opt pre-existing vessels. 
Additionally, the state of the endothelium may contribute to the formation of any of these 
tumor-vessel structures. For example, if the endothelium had a net increase in cell death 
rate, it could facilitate the integration of tumors within the vasculature. On the other hand, 
if the rate of proliferation was higher and the overall state of the vessel was intact, tumors 
could interact with the endothelium by constricting or pulling on the vessel wall. Our 
experimental approach enables a convenient way to study multiple steps in the metastatic 
cascade that are otherwise very difficult to observe in vivo. Moreover, this tumor-
microvessel model could also be adapted and customized to reflect other aspects of the 





Materials and methods  
Mice and cell lines 
Mice used in this study were backcrossed onto and maintained on the FVB/n background 
in a specific pathogen-free facility. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) 
mice and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse lines were acquired from the 
Jackson Laboratory (22). Mouse husbandry and procedures were all conducted according 
to an animal protocol approved by the Johns Hopkins University School of Medicine 
Institutional Animal Care and Use Committee. For confocal time-lapse experiments, 
MMTV-PyMT mice were crossed with FVB/NJ, mT/mG mice (23). 
VeraVec HUVEC-TURBO-GFP (HUVEC-GFP) (HVERA-UMB-202100; Angiocrine 
Bioscience, New York, NY) were seeded in the cylindrical channel of the microvessel 
platform (24).  Endothelial cells were grown in “normal growth medium” (NGM): MCDB 
131 (Caisson Labs, Carlsbad, CA) supplemented with 10% heat inactivated fetal bovine 
serum (F0926; Sigma), 25 mg/mL endothelial mitogen (BT-203, Biomedical 
Technologies), 2 U/mL heparin (Sigma), 1 µg/mL hydrocortisone, 0.2 mM ascorbic acid 
2-phosphate (Sigma), and 1% penicillin-streptomycin-glutamine (Life Tech). All culture 
conditions were in humidified environments with 5% CO2 at 37°C. All cell lines were 
authenticated by their respective manufacturers and tested negative for mycoplasm. 
Isolation of primary mammary tumor organoids 
Primary tumor organoids were isolated from mammary tumors by a combined mechanical 
and enzymatic digestion using collagenase (C2139; Sigma-Aldrich) and trypsin (27250-
018; Gibco Life Technologies) as previously described (16, 25). In brief, tumors were 
harvested from 8- to 10-wk-old mice, minced with a scalpel, and digested for 1 h at 37°C 
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in collagenase solution: DMEM (10565-018; Gibco Life Technologies) with 2 mg/mL 
collagenase, 2 mg/mL trypsin (27250-018; Gibco LifeTechnologies), 5 %(vol/vol) FBS 
(F0926; Sigma-Aldrich), 5 μg/mL insulin (I9278; Sigma-Aldrich), and 50 μg/mL 
gentamicin (15750; Gibco Life Technologies). The suspension was centrifuged at 1500 
rpm for 10 min to remove cellular debris, and the pellet was treated with 2 U/μL DNase 
(D4263; Sigma-Aldrich). Tumor organoids were separated from single cells by differential 
centrifugation. For control experiments, tumor organoids were embedded in 7mg/mL rat 
tail collagen-I (354249, Corning) gels at 2-3 organoids/µL as 150µL suspensions an plated 
in a 24-well multiwell glass bottom plate (662892; Greiner Bio-One). Each well was 
cultured with “organoid media”: DMEM/F12 (10565-018, Gibco), 1% v/v insulin, 
transferrin, selenium (51500, ThermoFisher) and 1% v/v penicillin/streptomycin (15140-
122, Gibco) supplemented with 2.5 nM FGF2 (F0291, Sigma).  
Fabrication of perfusable microvessel device 
The microvessel platform is fabricated as previously described (21). Briefly, high 
concentration of rat tail collagen I (354249, Corning) is diluted to 7 mg/mL and neutralized 
with DI water, 10x PBS, and 1 N sodium hydroxide.  After neutralization, tumor organoids 
are embedded into the collagen gel solution to a final concentration of 5 organoids/µL and 
randomly seeded surrounding a 150 μm diameter super-elastic nitinol wire (Malin Co.) 
within a Sylgard 184 polydimethylsiloxane (PDMS; Dow Corning) housing which is 
patterned using a custom-made aluminum mold.  After 45 min gelation at 37°C, the rod is 
removed, leaving behind a cylindrical channel within the collagen gel.  The channel is 
subsequently coated with fibronectin (50 µg/mL, F2006; Sigma) to promote endothelial 
adhesion and spreading.  Endothelial cells in suspension are introduced into the channel at 
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a concentration of 5 x 10-7 cells/mL and allowed to settle and actively adhere to the channel 
walls.  After the endothelial cells have spread for about 2 h, NGM is perfused through the 
vessel at a physiological relevant shear stress of approximately 4 dynes/cm2 under a steady 
laminar flow at a rate of 1 mL/h (Fig. 2). The devices are then tested for functional 
properties, such as vessel permeability and expression of relevant junctional proteins.  
In order to fix the distance of the tumor to the vessel, a slight modification was added to 
the platform described above. A second cylindrical template rod is introduced within the 
PDMS housing parallel to the first template rod (Fig. 6). Once the two rods are placed into 
the PDMS housing, the collagen solution is introduced and allowed to gel for 45 min at 
37°C. Tumor organoids are then embedded at high concentration in 3mg/mL collagen I 
gels (354236, Corning) and introduced into the inlet. One of the rods is then slowly 
removed allowing the introduction of the tumor suspension into the cylindrical channel. 
The devices are then incubated for 15-20 min at 37°C. The second channel is then removed 
following the steps described above for vessel formation.  
Microscopy and image analysis  
Whole slide tissue scan for in vivo analysis was performed on 40 µm sections of orthotopic 
tumors mounted onto positively-charged slides. Stained slides were mounted with 
Fluoromount Aqueous Mounted Medium (Sigma; F4680) and covered with rectangular 
#1.5 High Precision 24x50mm, 170µm-thick Microscope Cover Glasses (Thor Labs; 
CG15KH). Mounted slides were then scanned with AxioScan.Z1 (Zeiss) using Zen Blue 
2.1 with the following configurations: Fluar 5x/0.27NA M27 objective for coarse focus 
mapping, Plan-Apochromat 20x/0.80NA M27 objective for fine focus mapping, 
Hamamatsu Orca Flash 4.0 (fluorescence) camera for image capture, and Colibri 7 VIS-
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LED fluorescent light source. To detect DAPI, mGFP, mTomato, and AlexaFluor 647, the 
following light sources and filter sets were used, respectively: 96 HE BFP (LED module 
385nm) at 50% intensity and 1.004ms exposure, Excitation BP 390/40 and  Emission BP 
450/40 filter; 38 HE GFP (LED module 475nm) at 50% intensity and 31.504ms exposure, 
Excitation BP 470/40 and Emission BP 525/50 filter; 43 HE DsRed (LED module 567nm) 
at 50% intensity and 17.204ms exposure, Excitation BP 550/25 and Emission BP 605/70 
filter; 50 Cy5 (LED module 630nm) at 50% intensity and 123.404 ms exposure, Excitation 
BP 640/30 and Emission BP 690/50 filter. Z-stacks were taken at every 1µm for a range of 
16µm (15 stacks), with scaling-per-pixel at 0.163µm x 0.163µm x 1µm, and stored in raw 
(.czi file) format with JpgXr lossless compression. ImageJ and Imaris software (Bitplane 
Scientific, Zurich, Switzerland) were used for image analysis and to adjust brightness and 
contrast across entire images to maximize image clarity.  
Microvessels were imaged on a Nikon TE-2000 U microscope (Nikon Instruments Inc., 
Melville, NY). Time-lapse fluorescence and phase-contrast images, tracer molecules for 
vessel permeability measurements and fluorescent proteins were excited with a Nikon 
Intensilight epifluorescence illuminator, detected with an ET Sedat Quad band 89000 filter 
set (Chroma Technology Corp, Bellows Falls, VT), using a 10x phase-contrast objective 
(N.A. 0.3), and captured with a Nikon DS-Qi1Mc camera. Confocal images were captured 
on a Zeiss 780 laser-scanning confocal microscope (Carl Zeiss Microscopy). Differential 
interference contrast (DIC) microscopy images were captured with an LD Plan-Neofluar 
20×/0.4 Korr Ph2 objective lens and a Cell Observer system with an AxioObserver Z1 and 
an AxioCam MRM camera (Carl Zeiss).  
Measurement of permeability and focal leaks  
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Upon formation and maturation of endothelial vessels, and tumor-vessel interactions, 
permeability was simultaneously measured for three different fluorescent molecular weight 
probes introduced into the input port through the vessel lumen at a final concertation of 
5ug/mL 3 kDa dextran (Alexa Flour-488-conjugated), 62.5 ug/mL 10 kDa dextran (Alexa 
Flour-647-conjugated) and 10 ug/mL 70 kDa dextran (Texas Red), respectivley. All 
fluorescently labeled dextran molecules were diluted in NGM prior to perfusion through 
the platform.  Widefield epifluorescence images capturing fluorophores introduced through 
the microvessels and leakage into the ECM were acquired with a 4x objective over at least 
1 h time period at 2 min intervals.  Calibration experiments were performed to optimize 
image acquisition such that a linear relation between concentration and fluorescence 
intensity was present at least 10 times above and below the perfused concentrations of 
tracer molecules.  
To measured permeability using 3D engineered microvessel devices, the following 
equation was used: P3D= (1/ΔIf) (dIf/dt) (d/4), where ΔIf is the initial increase in 
fluorescence intensity (when the vessel is being filled with the fluorescent probe),  (dIf/dt) 
is the rate of increase in fluorescence intensity as the solute is being transported from the 
vessel to the ECM and d is the diameter of the vessel (26). Permeability coefficients were 
calculated in cm/s. The fluorescent intensity values obtained over time were divided in 3 
regions: (i) the “noise region” (prior to the vessel being filled with the fluorescent probe), 
(ii) when the vessel is being filled with the fluorescent probe (ΔIf), and iii) when the 
fluorescent probe permeates into the ECM (Fig. 3). In order to automate the calculation of 
permeability an algorithm was developed to calculate permeability coefficients for all 
fluorescent molecular probes. Each microvessel time-lapse image was divided in ten region 
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of interest (ROI) of equal size and the fluorescent intensity values were calculated over 
time for the different fluorescent probes using Fiji. Once all data values were obtained, the 
strategy was to find the inflection point marking the transition where the vessel has been 
completely filled with fluorescent dye and starts the diffusion towards the ECM. In order 
to properly find the relevant inflection point, a polynomial of degree six was used to fit the 
data for each of the ROIs and each fluorescent probe. The “noise region” was excluded 
from the original data to ensure a good fit of the polynomial and to better estimate the 
relevant inflection point. To properly identify the “noise region” the following iterative 
approach was used. This step starts by using all data available and continues excluding data 
by applying the absolute value of the growth rate of the fluorescent intensity (using 1% 
increments). Following this procedure in an iterative manner, the data that was finally used 
to fit the polynomial was selected after the inflection points identified became stable after 
at least three iterations. In case one or more inflection point(s) was/were identified, the 
relevant inflection point for our analysis was determined as the first one where the second 
derivate changed from negative to positive (concave down to concave up). If the inflection 
point of interest was not found the data for such ROI was not used.  Once the relevant 
infection point was identified, the ΔIf was determined and (dIf/dt) was calculated after the 
relevant inflection point using all available data stopping if a subsequent inflection point 
was found.   
Focal leaks were calculated as previously described (26). Briefly, the contrast in the 
fluorescence images taken for the permeability assay was maximized to examine for any 
nonuniformities (i.e., excess of fluorescence intensity regions) in the length of the 
microvessel. Focal leaks (FL) were quantify overtime using the following equation: FL= 
μ
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OCT blocks were sectioned at 40 μm thickness using a Leica cryostat (Leica Biosystems) 
set to −27 °C. Sections were placed on Superfrost Plus Gold microscope slides (15-188-
48; Fisherbrand) and stored at -80°C. For antibody staining, slides were thawed at ambient 
temperature, rinsed twice with PBS to remove OCT and permeabilized with 0.5% Triton 
X-100 for 1 h. Samples were then blocked with 10% FBS/ 1% BSA in PBS for 2-3 h and 
incubated with primary antibody solution overnight at 4°C in 1% FBS/ 1%BSA in PBS. 
Slides were then rinsed twice in PBS with 10% FBS/1% BSA and then incubated with 
secondary antibodies diluted in PBS with 1%FBS/ 1% BSA overnight at 4°C. Slides were 
rinsed twice in PBS with 1% FBS/1% BSA for 10 min and once in PBS for 10 min. Slides 
were mounted using Fluoromount Aqueous Mounted Medium (Sigma; F4680) and covered 
with rectangular #1.5 High Precision 24x50 mm, 170 µm-thick Microscope Cover Glasses 
(Thor Labs; CG15KH). Immunofluorescent staining for each antibody was done for at least 
three independent biological replicates. Rabbit anti-CD31 (Abcam; ab28364; 1:100) were 
used as primary antibodies. Goat anti-rabbit AlexaFluor 647 (ThermoFisher; A32733; 
1:200) were used as secondary antibodies. Nuclei were stained with DAPI (Roche; 
10236276001; 1:1000).  
Immunofluorescence staining for microvessel devices was performed within the vessel 
platform. The vessels were washed with PBS for 5 min, fixed with 3.7% paraformaldehyde 
(Sigma) for 15 min, permeabilized with 0.1% Triton X-100 (Sigma) for 15 min, and 
blocked with 10% FBS overnight at 4 °C. Microvessels were incubated overnight at 4 °C 
with anti-β-catenin (E-5) primary antibody (Santa Cruz, sc-7963,1:300) and for 20 min at 
room temperature with goat anti-Mouse IgG (H+L), Alexa Fluor Plus 488 (ThermoFisher 
Scientific, A32723, 1:100). Nuclei was stained using DAPI solution (Invitrogen, D3571,  
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1:1000). Confocal z-stack images were captured on a Zeiss 780 laser-scanning confocal 
microscope (Carl Zeiss Microscopy). To fully reconstruct microvessels, approximately 
four hundred 0.5 μm slices were acquired using a 40X objective. 
Endothelial cell proliferation and cell death analysis 
Phase-contrast and fluorescence time-lapse images were captured every 20 min and 
analyzed using Fiji. Endothelial monolayers located at the top and bottom regions of the 
vessel were analyzed for proliferation and cell death events (27-29).  Proliferating cells 
were distinguished by the increased rounding in the cell shape prior to cell division that 
generates a visible halo around the cell body that can be follow until the two daughter cells 
reincorporate into the monolayer (Supplemental Fig. 3, Supplemental Movie 8).  The 
number of endothelial cell divisions was counted along three different regions per vessel 
overtime and was divided by the total number of cells within the assessed region of the 
monolayer at the beginning of the time-lapse. The rate of cell proliferation is calculated as 
percent per hour (% cell division/h).  Endothelial cell death was also detected by direct 
observation of individual cells within the monolayer detaching and producing a cellular 
debris that is taken by the flow during the preceding frames. Similar to the endothelial cell 
proliferation the rate of cell death is calculated as percent per hour (% cell death/h; 
Supplemental Fig. 3) 
Statistics 
All statistical analyses were conducted using STATA or Graphpad Prism. STATA was 
used to create the algorithm to calculate permeability. Data was evaluated for normality 
using D'Agostino-Pearson omnibus test. P value was determined by one-way ANOVA or 
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Mann-Whitney test if the data did not present a normal distribution. P <0.05 was considered 
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Figure 4-1. Identification of mosaic vessels in primary metastatic breast cancer 
tumors. ROSAmTmG; MMTV-PyMT tumor organoids were transplanted into nonfluorescent 
NSG host mice to unambiguously identify tumor tissue in contact with vessels stained with 
anti-CD31 (green). (A) Representative 2D projection of a fluorescence z-stack image of a 
primary tumor section showing vessels stained with anti-CD31 (green) and DAPI (52). (B) 
2D projection of a fluorescence z-stack image of a primary tumor section showing a 
partially lined vessel in which tumor cells are in apparent contact with the vessel lumen 
(arrowheads mark a region lacking detectable CD31 immunoreactivity) and, (C) a fully 
lined vessel. Scale bar: 30 µm. (D) Representative 3D projection of a fluorescence z-stack 
image of a primary tumor section stained with PECAM-1/CD31 (green) and DAPI. (E) 3D 
projection of a fluorescence z-stack image of a primary tumor section showing a mosaic 
vessel in which tumor cells are in apparent contact with the vessel lumen (arrowheads mark 
a region lacking detectable CD31 immunoreactivity) and, (F) a fully lined vessel. Scale 
bar: 30 µm. Tissue depth between each section, 1µm. Total tissue depth, 16 µm. 
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Figure 4-2. Coculture of mammary gland tumor organoids into a perfusable 3D 
microvessel platform.  
(A) Schematic representation of 3D organotypic culture of ROSAmTmG; MMTV-PyMT 
tumor organoids seeded into a vessel device. (B) Schematic illustration of the side- and 
end-view of a 150 µm diameter microvessel design and fabrication. Tumor organoids 
embedded in collagen-I gels are seeded surrounding a cylindrical metal rod. After the 
tumor/collagen solution gels, the rod is removed resulting in a bare channel which is 
perused with media and coated with fibronectin. Endothelial cells are then seeded resulting 
in a confluent 3D microvessel. The perfusion system is by gravity flow by differential 
pressure. Flow is kept at 1 mL/hour and a shear stress of 4 dynes/cm2. (C) Schematic 
illustration of imaging focused at the mid-plane of the vessel and the resulting 2D projected 
image (right). The vessel appears hollow and media through the vessel lumen can diffuse 
out into the ECM (D) Confocal image of a vessel stained with b-catenin (green) and DAPI. 
Images show three focal planes: side view, mid-plane and a cross-section (end-view) of a 
z-stack image. (E) Fluorescence microscopy image of tumor organoids (red) embedded in 
collagen-I solution surrounding a vessel (green). (F) Inset showing a 3D cross-section of a 
confocal z-stack image of tumor organoids near a vessel. Arrow, direction of flow.  Scale 









Figure 4-3. Microvessel integrity and functionality in the presence of tumor 
organoids. Representative fluorescence time-lapse microscopy images of a microvessel 
co-cultured with ROSAmTmG; MMTV-PyMT tumor organoids and control without tumor 
organoids. Permeability was assessed by simultaneously perfusing three different 
fluorescent molecular weight probes through the vessel lumen. (A-D) 70 kDa dextran 
(Texas Red). Time = 0 min represents the frame prior to luminal filling (A’-D’) which 
occurs on average at 20 min. (A”-D”) After luminal filing the fluorescence probes perfuse 
out of the vessel into the ECM. (E) Permeability of 70 kDa dextran molecular probe 
increases in the presence of tumor organoids compared to control vessel devices without 
tumor organoids and decreases when treated with 400 µM dibutyryl-cAMP (db-cAMP) for 
24 h. n= number of permeability values calculated for at least 3 biological replicates. Error 
bars indicate s.e.m. P values were determined by the Mann-Whitney test. Differences were 
considered statistically significant for p< 0.05. Images and analysis of the other two 
molecular probes in Supplemental Fig. 2. (F-F’) Representative fluorescence time-lapse 
microscopy images of a vessel cocultured with tumor organoids with poor barrier function 
showing transient focal leaks of 10 kDa dextran(Alexa Flour-647-conjugated) probe after 
luminal vessel filling. The arrows indicate focal leaks along the vessel wall through time. 
These transient leaks are likely due to temporary disruption at cell-cell junctions, which is 
consistent with a molecular cut off size larger than 3 kDa suggesting paracellular transport. 
The flow rate is kept at 1mL/hour and at a shear stress of 4 dynes/cm2. The direction of 
the flow is from the left to the right of the images. (G) The average number of focal leaks 
per mm of microvascular vessel increases in the presence of tumor organoids compared to 
control vessel devices and decreases upon treatment with db-cAMP. n= number of vessel 
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devices for 3 biological replicates. Error bars indicate s.e.m. P values were determined by 
the Mann-Whitney test. Differences were considered statistically significant for p< 0.05. 
(H) Positive correlation between focal leaks and permeability. The measure Corr(P3D, 
Focal leaks) indicates the so called Pearson's correlation coefficient which is a measure of 
the strength and direction of association that exists between two continuous variables. It 
ranges between -1 (perfect negative association) to 1 (perfect positive association). A value 
of 0 would indicate no association between two continuous variables. Representative 





Figure 4-3.  
  



































































































70 kDa dextran 
0 min 0 min
200 μm 200 μm
C D
NGM +db-cAMP
Control (w/o tumor orgaoids) Tumor orgaoids
0 min 0 min
200 μm 200 μm
A B
20 min 20 min
200 μm 200 μm
Aʹ Bʹ
40  min 40 min





6 min 16 min 32 min



















10 kDa dextran 
 157 
Figure 4-4. Tumor organoids integrate with the endothelial vessel wall and are the 
most frequent type of tumor-vessel interactions in vitro. Representative fluorescence 
time-lapse images of a ROSAmTmG; MMTV-PyMT tumor organoid growing near a 
microvessel (green). Direction of the flow is from left to right of the images. (A) Tumor 
organoid integrates with the vessel wall forming a mosaic vessel by day 6 in culture. The 
tumor cells are exposed to the vessel flow which is kept at 1mL/hour and at a shear stress 
of 4 dynes/cm2. (A') 3D cross-section at the site of mosaic vessel formation. Scale bar: 100 
µm. Arrowhead marks a region lacking endothelial cell lining. (B) Tumor organoid 
growing near a microvessel (behind the vessel in the image) completely constricts the 
vessel. By day 5 the flow rate decreased to less than 0.1 mL/h, resulting in increased 
intraluminal pressure reflected by upstream vessel expansion (B') 3D cross-section at the 
site of vessel constriction. Scale bar: 50 µm. Arrowhead marks a region of vessel 
contriction. (C) Tumor organoid deforms vessel wall by pulling on the endothelium by day 
2 in culture. (C') 3D cross-section of a vessel pull. Scale bar: 100 µm. (D) Fluorecence 
time-lapse images showing retention of barrier function at site of tumor organoid contact 
with vessel wall. Vessel barrier function was assessed by perfusing two different 
fluorescent molecular weight probes through the vessel lumen: (D-F) 3 kDa dextran (Alexa 
Flour-488-conjugated), (D'-F') 10 kDa dextran (Alexa Flour-647-conjugated). Time= 0 
min represents the frame prior to luminal filling. At 20 min. of luminal filling we observe 
retention of the tracer molecules at the site where the tumor organoid is in contact with the 
vessel wall suggesting the formation of a tumor-endothelial cell junction. Scale bar: 50 µm. 
(H) Quantification of tumor-vessel interactions showing mosaic vessels as the most 
frequent type observed in vitro compared to vessel constriction and vessel pull. Treatment 
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with db-cAMP for 24 h decreases the number of interactions observed. Mosaic vessel 
number was determined by the retention of 10 kDa dextran (Alexa Flour-647-conjugated) 
as described in D-F. NGM: Normal growth medium. n= number of vessel devices for at 
least 3 biological replicates. Error bars indicate s.e.m. P values were determined by the 
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Figure 4-5. Intravasation of a tumor cluster preceded by mosaic vessel formation. 
Frames from a representative (A) phase contrast and (B) fluorescent microscopy time-lapse 
movie of a ROSAmTmG; MMTV-PyMT tumor organoid and a HUVEC microvessel (GFP). 
(A’) Insets of phase and (B’) fluorescent microscopy time-lapse images showing a tumor 
cluster shedding into the vessel lumen under continuous flow (yellow arrows). The flow 
rate is kept at 1mL/hour and at a shear stress of 4 dynes/cm2. The direction of the flow is 
from the left to the right of the images. Scale bars: (A-B) 200 µm, (A’-B’) 
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Figure 4-6. Tumors integrate with the endothelial vessel wall in a perfusable 3D 
microvessel platform with a parallel tumor-vessel arrangement.  
(A) Schematic representation of 3D organotypic culture of ROSAmTmG; MMTV-PyMT 
tumor organoids seeded into a vessel device using a parallel tumor-vessel arrangement. (B) 
Schematic illustration of the side- and end-view of a 150 µm diameter microvessel design 
and fabrication. In order to fix the distance of the tumor to the vessel, a second cylindrical 
template rod is introduced into the microvessel platform and the collagen solution is 
introduced surrounding both rods. Tumor organoids at a high concertation are embedded 
in lower density collagen-I gels and are introduced into one of the inlets. One of the rods 
is then slowly removed allowing the introduction of the tumor/collagen gel suspension into 
the cylindrical channel. After the tumor/collagen solution gels, the second rod is removed 
resulting in a bare channel which is perfused with media and coated with fibronectin. 
Endothelial cells are then seeded resulting in a confluent 3D microvessel. The perfusion 
system is by gravity flow by differential pressure. Flow is kept at 1 mL/h and a shear stress 
of 4 dynes/cm2. (C) Schematic illustration of imaging focused at the mid-plane of the vessel 
and the resulting 2D projected image (right). (D) Fluorescence microscopy image of a 
ROSAmTmG; MMTV-PyMT tumor filled channel and a HUVEC microvessel (GFP) 
focusing at mid-plane. (E) Frames from a representative fluorescent microscopy time-lapse 
movie of a collective tumor strand that integrates with the vessel wall forming a mosaic 
vessel. The tumor cells are exposed to the vessel flow which is kept at 1mL/hour and at a 





Figure 4-7. Applications of the co-culture of tumor organoids into a perfusable 3D 
microvessel platform.  
(A) Tumor-microvessels model represent a reductive approach to analyze the metastatic 
process in the context of a 3D platform that introduces physiological relevant geometry 
and multicellular dimensionality to study the tumor microenvironment. Tumor organoids 
only or coculture with varying stromal cells can be introduced into a 3D microvessel 
platform that has a functional vessel lined with endothelial cells with perfusion adapted for 
live cell imaging. This model can be used to study many aspects of cancer progression, 
including tumor-vessel interactions (mosaic vessel, vessel constriction and vessel pull) 
over time, imaging, collecting and analyzing intravasated tumor cells/clusters, and the 
changes in endothelium homeostasis. (B) Cartoon representations of the three tumor-vessel 
interactions that can be model using the 3D microvessel platform and the possible 




Supplemental Figure 4-1. Effects of endothelial medium on tumor organoid growth 
and structure.  
(A) Schematic representation of 3D organotypic culture of ROSAmTmG; MMTV-PyMT 
tumor organoids using the same culture conditions in the 3D microvessel device. Organoids 
from the same mouse were culture either with “organoid media” or endothelial medium 
with or without dibutyryl-cAMP (db-cAMP) for 5 days. (B-E) Representative still images 
of tumor organoids for Day 0 (control) and, Day 5 in culture for organoid media 
supplemented with bFGF, endothelial medium and endothelial medium with db-cAMP, 
respectively. Scale bar: 50 µm. (F) Tumor organoid growth was evaluated by measuring 
the projected surface area at Day 0 and Day 5. (G) Mean circularity score. n= number of 
tumor organoids, r= 2 biological replicates. Error bars indicate s.e.m. P values were 
determined by the Mann-Whitney test. Differences were considered statistically significant 
for p< 0.05 (H) representative fluorescence still images of tumor organoids cultured in a 
microvessel device at Day 1 and Day 3 in culture. Flow is kept at 1 mL/hour and a shear 
stress of 4 dynes/cm2. The direction of the flow is from left to right of the image. Scale bar: 
50 µm. (I) Tumor organoid growth within microvessel devices were evaluated by fold 
increase in projected surface area of organoid at Day 5 divide by Day 1 in culture. n= 
number of tumor organoids for at least 3 biological replicates. Error bars indicate s.e.m. P 
values were determined by the Mann-Whitney test. Differences were considered 




Supplemental Figure 4-2. Microvessel integrity and functionality in the presence of 
tumor organoids.  
Representative fluorescence time series microscopy images of a vessel device cocultured 
with ROSAmTmG; MMTV-PyMT tumor organoids. Permeability was assessed by 
simultaneously perfusing three different fluorescent molecular weight probes through the 
vessel lumen: (A-D) 3 kDa dextran (Alexa Flour-488-conjugated), (53)10 kDa dextran 
(Alexa Flour-647-conjugated). Time = 0 min represents the frame prior to luminal filling 
(A’-D’ and F’-I’) which occurs on average at 20 min. (A”-D” and F”-I”) After luminal 
filing the fluorescence probes perfuse out of the vessel into the ECM. (E and J) 
Permeability of 3 kDa and 10 kDa dextran molecular probes increases in the presence of 
tumor organoids compared to control vessel devices without tumor organoids and 
decreases when treated with 400 µM dibutyryl-cAMP (db-cAMP) for 24 h. n= number of 
permeability values calculated for at least 3 biological replicates. Error bars indicate s.e.m. 
P values were determined by the Mann-Whitney test. Differences were considered 
statistically significant for p< 0.05 
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Supplemental Figure 4-3. Endothelial cell proliferation and cell death within a 3D 
tumor-microvessel model in the presence of tumor organoids.  
(A) Schematic illustration of imaging focused at the side view of the microvessel. 
Individual cell mitosis and death can be visualized and analyzed within the projected 
endothelium. (B) Representative time-lapse movie of phase-contrast images of an 
enothelial cell undergoing mitosis. (C) endothelial cell proliferation rates within the 
microvessel. (D) Representative time-lapse movie of phase-contrast images of an 
endothelial cell undergoing cell death. (E) endothelial cell death rates within the 
microvessel. Proliferation and cell death rates are reported as %/h. Scale bar: 30 µm. n= 
number of devices for at least three biological replicates. Error bars indicate s.e.m. P values 
were determined by the Mann-Whitney test. Differences were considered statistically 











Conclusions related to modeling breast cancer metastasis using a 3D 





Breast cancer is the second leading cause of cancer-related mortality in women, 
predicted to cause about 40,000 death in women in the US (American Cancer Society. 
Breast Cancer Facts & Figures 2015-2016). This, in part, is the result of a lack of a clear 
understanding of the mechanisms that govern the metastatic process. Cancer metastasis is 
a complex process that involves a series of steps including invasion, dissemination, 
intravasation and colonizing a secondary site. One of the challenges in studying metastasis 
is that certain steps, like tumor cell/cluster intravasation are difficult to observe or 
manipulate in vivo. To overcome this challenge, we developed a microfluidic device that 
enabled co-culture of tumor organoids with a functional vessel in the context of an ECM 
that models the relevant tumor microenviroment. 
 
This work aimed to analyze the dynamics of tumor invasion and intravasation using 
a 3D microvessel platform that allows visualization and real-time monitoring of tumor-
vessel interactions (1, 2). The motivation for this work started with a collaboration with 
Dr. Kevin Cheung (described in Chapter 3) were we found that polyclonal breast cancer 
metastases originated form the invasion and dissemination of collective tumor epithelium 
(3). This result challenged the conventional model of cancer metastasis where 
dissemination, intravasation and colonization of distant sites is described to occur through 
a single tumor cell intermediate. Although we found tumor cell clusters to be rare in our 
tumor mouse model, we found that tumor clusters have a higher metastatic potential (>100-
fold) compared to single tumor cells in vivo.  Furthermore, aggregating tumor cells into 
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clusters showed > 15-fold increase in colony formation in vitro. These findings are in 
agreement with clinical studies linking circulating tumor cell clusters with worse patient 
survival (4).  
 
Previous animal and clinical studies have shown that trauma or massage to the 
primary tumor increases the number of intravasated single tumor cells and clusters (5). 
Moreover, CTCs and CTMs were shown to shed into the circulation during tumor resection 
and, consequently, soft tumor manipulation decreased the risk of metastatic lesions (6-9). 
Additionally, it was suggested that once inside the vessel, tumor clusters might be limited 
by the size of the tumor vessel to survive and travel to distant sites (10). Recent studies 
showed that over 90% of tumor clusters containing up to 20 cells were able to traverse 5 to 
10 µm constrictions even in whole blood (11). Using both microfluidics and in vivo 
zebrafish models this study demonstrated that tumor clusters could reorganized in single 
chains and transit through capillary-sized vessel (11). These observations caused us to think 
about the ways in which tumors interact with the vasculature to allow the intravasation of 
polyclonal tumor cell clusters. 
 
Recent advances in microfluidics, particularly in the development of microvessel 
models that recapitulate perfusable human microvasculature provides unique tools for 
visualizing the physical and biological factors governing the metastatic process (2, 12, 13). 
Since tumor vasculature develops relatively quickly, it can lack components of normal 
microvessels, such as smooth muscle cells, pericytes, and lymphatics (14). As a result, the 
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tumor microvasculature is leakier, with chaotic vessel structures, and with frequent vessel 
with larger diameters (15).  
 
Using a 3D microfluidic platform to model the tumor microenvironment, we 
embedded tumor organoids in a collagen-I gel surrounding a functional microvessel under 
constant perfusion and shear stress. We were able to observe and monitor the formation of 
three types of tumor-vessel interactions: mosaic vessels (i.e., partial endothelial cell lining), 
vessel constriction and vessel pull. Furthermore, we found that mosaic vessels are the most 
frequent type of tumor-vessel interaction observed in vitro compared to vessel constriction 
and vessel pull. The presence of tumor cells within tumor vasculature has long been 
reported in fixed tissue sections and it has been speculated to contribute to tumor cell 
intravasation, but the dynamics of this process were never studied (17). Here, we visualized 
in real-time the formation of a mosaic vessel, followed by the passive shedding of a cancer 
cell cluster. This result indicates that passive shedding can occur at sites of mosaic vessels, 
and it implies that active tumor cell migration through the stroma towards the vasculature 
may not be required. These results agree with previous studies that demonstrates that 
intravasation occurs mostly within the tumor core where tumors are in direct contact with 
the vasculature (18). 
 
We also were able to model vascular constriction and vessel pull. The associated 
mechanical stresses could potentially facilitate intravasation through disruption of vessel 
structure or drive hypoxia through disruption of vessel function (19, 20). Furthermore, we 
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also observed tumors pulling on the vessel wall which may indicate sites of endothelial cell 
sprouting or the formation of vessel defects such as dead-ends (2). 
 
In sum, our work reveals the dynamics of tumor-vessel interactions using a 3D 
microvessel model that contains primary murine breast cancer tissue. Our studies provide 
a platform to further investigate tumor-vessel interactions by incorporating other 
components of the tumor microenvironment, such us immune cells.  This platform also 
provides a way to test the effects of cancer therapeutics at the vascular-tumor interphase. 
A better understanding of these interactions may help to elucidate the anti-vascular effects 
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